Prosthetic heart valve device and associated systems and methods

Information

  • Patent Grant
  • 11654021
  • Patent Number
    11,654,021
  • Date Filed
    Wednesday, June 17, 2020
    3 years ago
  • Date Issued
    Tuesday, May 23, 2023
    11 months ago
Abstract
A method for treating a native valve of a human heart having a native annulus and native leaflets includes positioning a capsule of a delivery device proximate a native heart valve. The method further includes partially deploying a prosthetic heart valve device from the capsule such that an inflow region of a valve support and an inflow region of a fixation structure are radially expanded. A portion of the prosthetic heart valve device remains coupled to the delivery device while a gap exists between a downstream end of a prosthetic valve disposed within the valve support and a distal terminus of the capsule such that fluid can flow through the prosthetic valve with the prosthetic heart valve device partially deployed. The method may further include recapturing the prosthetic heart valve device within the capsule.
Description
TECHNICAL FIELD

The present technology relates generally to prosthetic heart valve devices. Several embodiments of the present technology are well suited for percutaneous repair and/or replacement of native mitral valves.


BACKGROUND

Heart valves can be affected by several conditions. For example, mitral valves can be affected by mitral valve regurgitation, mitral valve prolapse and mitral valve stenosis. Mitral valve regurgitation is abnormal leaking of blood from the left ventricle into the left atrium caused by a disorder of the heart in which the leaflets of the mitral valve fail to coapt into apposition at peak contraction pressures. The mitral valve leaflets may not coapt sufficiently because heart diseases often cause dilation of the heart muscle, which in turn enlarges the native mitral valve annulus to the extent that the leaflets do not coapt during systole. Abnormal backflow can also occur when the papillary muscles are functionally compromised due to ischemia or other conditions. More specifically, as the left ventricle contracts during systole, the affected papillary muscles do not contract sufficiently to effect proper closure of the leaflets.


Mitral valve prolapse is a condition when the mitral leaflets bulge abnormally up in to the left atrium. This can cause irregular behavior of the mitral valve and lead to mitral valve regurgitation. The leaflets may prolapse and fail to coapt because the tendons connecting the papillary muscles to the inferior side of the mitral valve leaflets (chordae tendineae) may tear or stretch. Mitral valve stenosis is a narrowing of the mitral valve orifice that impedes filling of the left ventricle in diastole.


Mitral valve regurgitation is often treated using diuretics and/or vasodilators to reduce the amount of blood flowing back into the left atrium. Surgical approaches (open and intravascular) for either the repair or replacement of the valve have also been used to treat mitral valve regurgitation. For example, typical repair techniques involve cinching or resecting portions of the dilated annulus. Cinching, for example, includes implanting annular or peri-annular rings that are generally secured to the annulus or surrounding tissue. Other repair procedures suture or clip the valve leaflets into partial apposition with one another.


Alternatively, more invasive procedures replace the entire valve itself by implanting mechanical valves or biological tissue into the heart in place of the native mitral valve. These invasive procedures conventionally require large open thoracotomies and are thus very painful, have significant morbidity, and require long recovery periods. Moreover, with many repair and replacement procedures, the durability of the devices or improper sizing of annuloplasty rings or replacement valves may cause additional problems for the patient. Repair procedures also require a highly skilled cardiac surgeon because poorly or inaccurately placed sutures may affect the success of procedures.


Less invasive approaches to aortic valve replacement have been implemented in recent years. Examples of pre-assembled, percutaneous prosthetic valves include, e.g., the CoreValve Revalving® System from Medtronic/Corevalve Inc. (Irvine, Calif., USA) and the Edwards-Sapien® Valve from Edwards Lifesciences (Irvine, Calif., USA). Both valve systems include an expandable frame and a tri-leaflet bioprosthetic valve attached to the expandable frame. The aortic valve is substantially symmetric, circular, and has a muscular annulus. The expandable frames in aortic applications have a symmetric, circular shape at the aortic valve annulus to match the native anatomy, but also because tri-leaflet prosthetic valves require circular symmetry for proper coaptation of the prosthetic leaflets. Thus, aortic valve anatomy lends itself to an expandable frame housing a replacement valve since the aortic valve anatomy is substantially uniform, symmetric, and fairly muscular. Other heart valve anatomies, however, are not uniform, symmetric or sufficiently muscular, and thus transvascular aortic valve replacement devises may not be well suited for other types of heart valves.





BRIEF DESCRIPTION OF THE DRAWINGS

Many aspects of the present disclosure can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale, and instead emphasis is placed on illustrating clearly the principles of the present disclosure. Furthermore, components can be shown as transparent in certain views for clarity of illustration only and not to indicate that the illustrated component is necessarily transparent. For ease of reference, throughout this disclosure identical reference numbers and/or letters are used to identify similar or analogous components or features, but the use of the same reference number does not imply that the parts should be construed to be identical. Indeed, in many examples described herein, identically numbered components refer to different embodiments that are distinct in structure and/or function. The headings provided herein are for convenience only.



FIG. 1 is a schematic, cross-sectional illustration of the heart showing an antegrade approach to the native mitral valve from the venous vasculature in accordance with various embodiments of the present technology.



FIG. 2 is a schematic, cross-sectional illustration of the heart showing access through the inter-atrial septum (IAS) maintained by the placement of a guide catheter over a guidewire in accordance with various embodiments of the present technology.



FIGS. 3 and 4 are schematic, cross-sectional illustrations of the heart showing retrograde approaches to the native mitral valve through the aortic valve and arterial vasculature in accordance with various embodiments of the present technology.



FIG. 5 is a schematic, cross-sectional illustration of the heart showing an approach to the native mitral valve using a trans-apical puncture in accordance with various embodiments of the present technology.



FIG. 6A is a cross-sectional side view and FIG. 6B is a top view schematically illustrating a prosthetic heart valve device in accordance with an embodiment of the present technology.



FIGS. 7A and 7B are cross-sectional side views schematically illustrating aspects of delivering a prosthetic heart valve device in accordance with an embodiment of the present technology.



FIG. 8 is a top isometric view of a prosthetic heart valve device in accordance with an embodiment of the present technology.



FIG. 9A is a side view of the prosthetic heart valve device of FIG. 8, and FIG. 9B is a detailed view of a portion of the prosthetic heart valve device shown in FIG. 9A.



FIG. 10 is a bottom isometric view of the prosthetic heart valve device of FIG. 9A.



FIG. 11 is a side view and FIG. 12A is a bottom isometric view of a prosthetic heart valve device in accordance with an embodiment of the present technology.



FIG. 12B is an isometric view of a prosthetic heart valve device in accordance with another embodiment of the present technology, and FIG. 12C is a detailed view of a portion of the heart valve device shown in FIG. 12B.



FIG. 13 is a side view and FIG. 14 is a bottom isometric view of the prosthetic heart valve device of FIGS. 11 and 12 at a partially deployed state with respect to a delivery device.



FIG. 15 is a bottom isometric view of a valve support for use with prosthetic heart valve devices in accordance with the present technology.



FIGS. 16 and 17 are side and bottom isometric views, respectively, of a prosthetic heart valve attached to the valve support of FIG. 15.



FIGS. 18 and 19 are side views schematically showing valve supports in accordance with additional embodiments of the present technology.



FIG. 20 is a schematic view of an arm unit of an anchoring member for use with prosthetic heart valve devices in accordance with the present technology.



FIG. 21 is a schematic view of an arm unit of an anchoring member for use with prosthetic heart valve devices in accordance with the present technology.



FIG. 22 is a schematic view of a portion of the arm units of FIGS. 20 and 21 in accordance with the present technology.



FIG. 23 is a schematic view of an arm unit of an anchoring member for use with prosthetic heart valve devices in accordance with the present technology.



FIGS. 24A and 24B are schematic views showing arms having difference configurations of eyelets for coupling a sealing member to an anchoring member in accordance with the present technology.





DETAILED DESCRIPTION

Specific details of several embodiments of the technology are described below with reference to FIGS. 1-19. Although many of the embodiments are described below with respect to prosthetic valve devices, systems, and methods for percutaneous replacement of a native mitral valve, other applications and other embodiments in addition to those described herein are within the scope of the technology. Additionally, several other embodiments of the technology can have different configurations, components, or procedures than those described herein. A person of ordinary skill in the art, therefore, will accordingly understand that the technology can have other embodiments with additional elements, or the technology can have other embodiments without several of the features shown and described below with reference to FIGS. 1-19.


With regard to the terms “distal” and “proximal” within this description, unless otherwise specified, the terms can reference a relative position of the portions of a prosthetic valve device and/or an associated delivery device with reference to an operator and/or a location in the vasculature or heart. For example, in referring to a delivery catheter suitable to deliver and position various prosthetic valve devices described herein, “proximal” can refer to a position closer to the operator of the device or an incision into the vasculature, and “distal” can refer to a position that is more distant from the operator of the device or further from the incision along the vasculature (e.g., the end of the catheter). With respect to a prosthetic heart valve device, the terms “proximal” and “distal” can refer to the location of portions of the device with respect to the direction of blood flow. For example, proximal can refer to an upstream position or a location where blood flows into the device (e.g., inflow region), and distal can refer to a downstream position or a location where blood flows out of the device (e.g., outflow region).


Overview


Several embodiments of the present technology are directed to mitral valve replacement devices that address the unique challenges of percutaneously replacing native mitral valves and are well-suited to be recaptured in a percutaneous delivery device after being partially deployed for repositioning or removing the device. Compared to replacing aortic valves, percutaneous mitral valve replacement faces unique anatomical obstacles that render percutaneous mitral valve replacement significantly more challenging than aortic valve replacement. First, unlike relatively symmetric and uniform aortic valves, the mitral valve annulus has a non-circular D-shape or kidney-like shape, with a non-planar, saddle-like geometry often lacking symmetry. The complex and highly variable anatomy of mitral valves makes it difficult to design a mitral valve prosthesis that conforms well to the native mitral annulus of specific patients. As a result, the prosthesis may not fit well with the native leaflets and/or annulus, which can leave gaps that allows backflow of blood to occur. For example, placement of a cylindrical valve prosthesis in a native mitral valve may leave gaps in commissural regions of the native valve through which perivalvular leaks may occur.


Current prosthetic valves developed for percutaneous aortic valve replacement are unsuitable for use in mitral valves. First, many of these devices require a direct, structural connection between the stent-like structure that contacts the annulus and/or leaflets and the prosthetic valve. In several devices, the stent posts which support the prosthetic valve also contact the annulus or other surrounding tissue. These types of devices directly transfer the forces exerted by the tissue and blood as the heart contracts to the valve support and the prosthetic leaflets, which in turn distorts the valve support from its desired cylindrical shape. This is a concern because most cardiac replacement devices use tri-leaflet valves, which require a substantially symmetric, cylindrical support around the prosthetic valve for proper opening and closing of the three leaflets over years of life. As a result, when these devices are subject to movement and forces from the annulus and other surrounding tissues, the prostheses may be compressed and/or distorted causing the prosthetic leaflets to malfunction. Moreover, a diseased mitral annulus is much larger than any available prosthetic aortic valve. As the size of the valve increases, the forces on the valve leaflets increase dramatically, so simply increasing the size of an aortic prosthesis to the size of a dilated mitral valve annulus would require dramatically thicker, taller leaflets, and might not be feasible.


In addition to its irregular, complex shape, which changes size over the course of each heartbeat, the mitral valve annulus lacks a significant amount of radial support from surrounding tissue. Compared to aortic valves, which are completely surrounded by fibro-elastic tissue that provides sufficient support for anchoring a prosthetic valve, mitral valves are bound by muscular tissue on the outer wall only. The inner wall of the mitral valve anatomy is bound by a thin vessel wall separating the mitral valve annulus from the inferior portion of the aortic outflow tract. As a result, significant radial forces on the mitral annulus, such as those imparted by an expanding stent prostheses, could lead to collapse of the inferior portion of the aortic tract. Moreover, larger prostheses exert more force and expand to larger dimensions, which exacerbates this problem for mitral valve replacement applications.


The chordae tendineae of the left ventricle may also present an obstacle in deploying a mitral valve prosthesis. Unlike aortic valves, mitral valves have a maze of cordage under the leaflets in the left ventricle that restrict the movement and position of a deployment catheter and the replacement device during implantation. As a result, deploying, positioning and anchoring a valve replacement device on the ventricular side of the native mitral valve annulus is complicated.


Embodiments of the present technology provide systems, methods and apparatus to treat heart valves of the body, such as the mitral valve, that address the challenges associated with the anatomy of the mitral valve and provide for repositioning and removal of a partially deployed device. The apparatus and methods enable a percutaneous approach using a catheter delivered intravascularly through a vein or artery into the heart, or through a cannula inserted through the heart wall. For example, the apparatus and methods are particularly well-suited for trans-septal approaches, but can also be trans-apical, trans-atrial, and direct aortic delivery of a prosthetic replacement valve to a target location in the heart. Additionally, the embodiments of the devices and methods as described herein can be combined with many known surgeries and procedures, such as known methods of accessing the valves of the heart (e.g., the mitral valve or triscuspid valve) with antegrade or retrograde approaches, and combinations thereof.


The devices and methods described herein provide a valve replacement device that can be recaptured in a delivery device after being only partially deployed to reposition and/or remove the device. The device also has the flexibility to adapt and conform to the variably-shaped native mitral valve anatomy while mechanically isolating the prosthetic valve from the anchoring portion of the device. Several embodiments of the device effectively absorb the distorting forces applied by the native anatomy. The device has the structural strength and integrity necessary to withstand the dynamic conditions of the heart over time, thus permanently anchoring a replacement valve. The devices and methods further deliver such a device in a less-invasive manner, providing a patient with a new, permanent replacement valve but also with a lower-risk procedure and a faster recovery.


Access to the Mitral Valve


To better understand the structure and operation of valve replacement devices in accordance with the present technology, it is helpful to first understand approaches for implanting the devices. The mitral valve or other type of atrioventricular valve can be accessed through the patient's vasculature in a percutaneous manner. By percutaneous it is meant that a location of the vasculature remote from the heart is accessed through the skin, typically using a surgical cut down procedure or a minimally invasive procedure, such as using needle access through, for example, the Seldinger technique. The ability to percutaneously access the remote vasculature is well known and described in the patent and medical literature. Depending on the point of vascular access, access to the mitral valve may be antegrade and may rely on entry into the left atrium by crossing the inter-atrial septum (e.g., a trans-septal approach). Alternatively, access to the mitral valve can be retrograde where the left ventricle is entered through the aortic valve. Access to the mitral valve may also be achieved using a cannula via a trans-apical approach. Depending on the approach, the interventional tools and supporting catheter(s) may be advanced to the heart intravascularly and positioned adjacent the target cardiac valve in a variety of manners, as described herein.



FIG. 1 illustrates a stage of a trans-septal approach for implanting a valve replacement device. In a trans-septal approach, access is via the inferior vena cava IVC or superior vena cava SVC, through the right atrium RA, across the inter-atrial septum IAS, and into the left atrium LA above the mitral valve MV. As shown in FIG. 1, a catheter 1 having a needle 2 moves from the inferior vena cava IVC into the right atrium RA. Once the catheter 1 reaches the anterior side of the inter-atrial septum IAS, the needle 2 advances so that it penetrates through the septum, for example at the fossa ovalis FO or the foramen ovale into the left atrium LA. At this point, a guidewire replaces the needle 2 and the catheter 1 is withdrawn.



FIG. 2 illustrates a subsequent stage of a trans-septal approach in which guidewire 6 and guide catheter 4 pass through the inter-atrial septum IAS. The guide catheter 4 provides access to the mitral valve for implanting a valve replacement device in accordance with the technology.


In an alternative antegrade approach (not shown), surgical access may be obtained through an intercostal incision, preferably without removing ribs, and a small puncture or incision may be made in the left atrial wall. A guide catheter passes through this puncture or incision directly into the left atrium, sealed by a purse string-suture.


The antegrade or trans-septal approach to the mitral valve, as described above, can be advantageous in many respects. For example, antegrade approaches will usually enable more precise and effective centering and stabilization of the guide catheter and/or prosthetic valve device. The antegrade approach may also reduce the risk of damaging the chordae tendineae or other subvalvular structures with a catheter or other interventional tool. Additionally, the antegrade approach may decrease risks associated with crossing the aortic valve as in retrograde approaches. This can be particularly relevant to patients with prosthetic aortic valves, which cannot be crossed at all or without substantial risk of damage.



FIGS. 3 and 4 show examples of a retrograde approaches to access the mitral valve. Access to the mitral valve MV may be achieved from the aortic arch AA, across the aortic valve AV, and into the left ventricle LV below the mitral valve MV. The aortic arch AA may be accessed through a conventional femoral artery access route or through more direct approaches via the brachial artery, axillary artery, radial artery, or carotid artery. Such access may be achieved with the use of a guidewire 6. Once in place, a guide catheter 4 may be tracked over the guidewire 6. Alternatively, a surgical approach may be taken through an incision in the chest, preferably intercostally without removing ribs, and placing a guide catheter through a puncture in the aorta itself. The guide catheter 4 affords subsequent access to permit placement of the prosthetic valve device, as described in more detail herein. Retrograde approaches advantageously do not need a trans-septal puncture. Cardiologists also more commonly use retrograde approaches, and thus retrograde approaches are more familiar.



FIG. 5 shows a trans-apical approach via a trans-apical puncture. In this approach, access to the heart is via a thoracic incision, which can be a conventional open thoracotomy or sternotomy, or a smaller intercostal or sub-xyphoid incision or puncture. An access cannula is then placed through a puncture in the wall of the left ventricle at or near the apex of the heart. The catheters and prosthetic devices of the invention may then be introduced into the left ventricle through this access cannula. The trans-apical approach provides a shorter, straighter, and more direct path to the mitral or aortic valve. Further, because it does not involve intravascular access, the trans-apical approach does not require training in interventional cardiology to perform the catheterizations required in other percutaneous approaches.


Selected Embodiments of Prosthetic Heart Valve Devices and Methods


Embodiments of the present technology can treat one or more of the valves of the heart, and in particular several embodiments advantageously treat the mitral valve. The prosthetic valve devices of the present technology can also be suitable for replacement of other valves (e.g., a bicuspid or tricuspid valve) in the heart of the patient. Examples of prosthetic heart valve devices, system components and associated methods in accordance with embodiments of the present technology are described in this section with reference to FIGS. 6A-19. Specific elements, substructures, advantages, uses, and/or other features of the embodiments described with reference to FIGS. 6A-19 can be suitably interchanged, substituted or otherwise configured with one another. Furthermore, suitable elements of the embodiments described with reference to FIGS. 6A-19 can be used as stand-alone and/or self-contained devices.



FIG. 6A is a side cross-sectional view and FIG. 6B is a top plan view of a prosthetic heart valve device (“device”) 100 in accordance with an embodiment of the present technology. The device 100 includes a valve support 110, an anchoring member 120 attached to the valve support 110, and a prosthetic valve assembly 150 within the valve support 110. Referring to FIG. 6A, the valve support 110 has an inflow region 112 and an outflow region 114. The prosthetic valve assembly 150 is arranged within the valve support 110 to allow blood to flow from the inflow region 112 through the outflow region 114 (arrows BF), but prevent blood from flowing in a direction from the outflow region 114 through the inflow region 112.


In the embodiment shown in FIG. 6A, the anchoring member 120 includes a base 122 attached to the outflow region 114 of the valve support 110 and a plurality of arms 124 projecting laterally outward from the base 122. The anchoring member 120 also includes a fixation structure 130 extending from the arms 124. The fixation structure 130 can include a first portion 132 and a second portion 134. The first portion 132 of the fixation structure 130, for example, can be an upstream region of the fixation structure 130 that, in a deployed configuration as shown in FIG. 6A, is spaced laterally outward apart from the inflow region 112 of the valve support 110 by a gap G. The second portion 134 of the fixation structure 130 can be a downstream-most portion of the fixation structure 130. The fixation structure 130 can be a cylindrical ring (e.g., straight cylinder or conical), and the outer surface of the fixation structure 130 can define an annular engagement surface configured to press outwardly against the native annulus. The fixation structure 130 can further include a plurality of fixation elements 136 that project radially outward and are inclined toward an upstream direction. The fixation elements 136, for example, can be barbs, hooks, or other elements that are inclined only in the upstream direction (e.g., a direction extending away from the downstream portion of the device 100).


Referring still to FIG. 6A, the anchoring member 120 has a smooth bend 140 between the arms 124 and the fixation structure 130. For example, the second portion 134 of the fixation structure 130 extends from the arms 124 at the smooth bend 140. The arms 124 and the fixation structure 130 can be formed integrally from a continuous strut or support element such that the smooth bend 140 is a bent portion of the continuous strut. In other embodiments, the smooth bend 140 can be a separate component with respect to either the arms 124 or the fixation structure 130. For example, the smooth bend 140 can be attached to the arms 124 and/or the fixation structure 130 using a weld, adhesive or other technique that forms a smooth connection. The smooth bend 140 is configured such that the device 100 can be recaptured in a capsule or other container after the device 100 has been at least partially deployed.


The device 100 can further include a first sealing member 162 on the valve support 110 and a second sealing member 164 on the anchoring member 120. The first and second sealing members 162, 164 can be made from a flexible material, such as Dacron® or another type of polymeric material. The first sealing member 162 can cover the interior and/or exterior surfaces of the valve support 110. In the embodiment illustrated in FIG. 6A, the first sealing member 162 is attached to the interior surface of the valve support 110, and the prosthetic valve assembly 150 is attached to the first sealing member 162 and commissure portions of the valve support 110. The second sealing member 164 is attached to the inner surface of the anchoring member 120. As a result, the outer annular engagement surface of the fixation structure 130 is not covered by the second sealing member 164 so that the outer annular engagement surface of the fixation structure 130 directly contacts the tissue of the native annulus.


The device 100 can further include an extension member 170. The extension member 170 can be an extension of the second sealing member 164, or it can be a separate component attached to the second sealing member 164 and/or the first portion 132 of the fixation structure 130. The extension member 170 can be a flexible member that, in a deployed state as shown in FIG. 6A, flexes relative to the first portion 132 of the fixation structure 130. In operation, the extension member 170 provides tactile feedback or a visual indicator (e.g., on echocardiographic or fluoroscopic imaging systems) to guide the device 100 during implantation such that the device is located at a desired elevation and centered relative to the native annulus. As described below, the extension member 170 can include a support member, such as a metal wire or other structure, that can be visualized during implantation. For example, the support member can be a radiopaque wire.



FIGS. 7A and 7B are cross-sectional views illustrating an example of the operation of the smooth bend 140 between the arms 124 and the fixation structure 130 in the recapturing the device 100 after partial deployment. FIG. 7A schematically shows the device 100 loaded into a capsule 700 of a delivery system in a delivery state, and FIG. 7B schematically shows the device 100 in a partially deployed state. Referring to FIG. 7A, the capsule 700 has a housing 702, a support 704, and a top 706. In the delivery state shown in FIG. 7A, the device 100 is in a low-profile configuration suitable for delivery through a catheter or cannula to a target implant site at a native heart valve.


Referring to FIG. 7B, the housing 702 of the capsule 700 has been moved distally such that the extension member 170, fixation structure 130 and a portion of the arms 124 have been released from the housing 702 in a partially deployed state. This is useful for locating the fixation structure 130 at the proper elevation relative to the native valve annulus A such that the fixation structure 130 expands radially outward and contacts the inner surface of the native annulus A. However, the device 100 may need to be repositioned and/or removed from the patient after being partially deployed. To do this, the housing 702 is retracted (arrow R) back toward the fixation structure 130. As the housing 702 slides along the arms 124, the smooth bend 140 between the arms 124 and the fixation structure 130 allows the edge 708 of the housing 702 to slide over the smooth bend 140 and thereby recapture the fixation structure 130 and the extension member 170 within the housing 702. The device 100 can then be removed from the patient or repositioned for redeployment at a better location relative to the native annulus A. Further aspects of prosthetic heart valve devices in accordance with the present technology and their interaction with corresponding delivery devices are described below with reference to FIGS. 8-19.



FIG. 8 is a top isometric view of an example of the device 100. In this embodiment, the valve support 110 defines a first frame (e.g., an inner frame) and fixation structure 130 of the anchoring member 120 defines a second frame (e.g., an outer frame) that each include a plurality of structural elements. The fixation structure 130, more specifically, includes structural elements 137 arranged in diamond-shaped cells 138 that together form at least a substantially cylindrical ring when freely and fully expanded as shown in FIG. 8. The structural elements 137 can be struts or other structural features formed from metal, polymers, or other suitable materials that can self-expand or be expanded by a balloon or other type of mechanical expander.


Several embodiments of the fixation structure 130 can be a generally cylindrical fixation ring having an outwardly facing engagement surface. For example, in the embodiment shown in FIG. 8, the outer surfaces of the structural elements 137 define an annular engagement surface configured to press outwardly against the native annulus in the deployed state. In a fully expanded state without any restrictions, the fixation structure 130 is at least substantially parallel to the valve support 110. However, the fixation structure 130 can flex inwardly (arrow I) in the deployed state when it presses radially outwardly against the inner surface of the native annulus of a heart valve.


The embodiment of the device 100 shown in FIG. 8 includes the first sealing member 162 lining the interior surface of the valve support 110, and the second sealing member 164 along the inner surface of the fixation structure 130. The extension member 170 has a flexible web 172 (e.g., a fabric) and a support member 174 (e.g., metal or polymeric strands) attached to the flexible web 172. The flexible web 172 can extend from the second sealing member 164 without a metal-to-metal connection between the fixation structure 130 and the support member 174. For example, the extension member 170 can be a continuation of the material of the second sealing member 164. Several embodiments of the extension member 170 are thus a floppy structure that can readily flex with respect to the fixation structure 130. The support member 174 can have a variety of configurations and be made from a variety of materials, such as a double-serpentine structure made from Nitinol.



FIG. 9A is a side view, FIG. 9B is a detailed view of a portion of FIG. 9A, and FIG. 10 is a bottom isometric view of the device 100 shown in FIG. 8. Referring to FIG. 9A, the arms 124 extend radially outward from the base portion 122 at an angle α selected to position the fixation structure 130 radially outward from the valve support 110 (FIG. 8) by a desired distance in a deployed state. The angle α is also selected to allow the edge 708 of the housing 702 (FIG. 7B) to slide from the base portion 122 toward the fixation structure 130 during recapturing. In many embodiments, the angle α is 15°-75°, or more specifically 15°-60°, or still more specifically 30°-45°. The arms 124 and the structural elements 137 of the fixation structure 130 can be formed from the same struts (i.e., formed integrally with each other) such that the smooth bend 140 is a continuous, smooth transition from the arms 124 to the structural elements 137. This is expected to enable the edge 708 of the housing 702 to more readily slide over the smooth bend 140 in a manner that allows the fixation structure 130 to be recaptured in the housing 702 of the capsule 700 (FIG. 7B). Additionally, by integrally forming the arms 124 and the structural elements 137 with each other, it reduces the potential of breaking the device 100 at a junction between the arms 124 and the structural elements 137 compared to a configuration in which the arms 124 and structural elements 137 are separate components and welded or otherwise fastened to each other. FIGS. 9A and 9B also show that the device 100 can further include chevron-support struts at the outflow region that extend between the arms 124 at the base 122 of the anchoring member 120. The chevron-supports at the base 122 do not necessarily have a “smooth bend,” such as the smooth bend 140 at the transition from the arms 124 to the downstream-most portion of the fixation structure 130. As such, so long as the chevron-supports and other elements of the device 100 project toward the inflow region to allow recapture, certain portions of the device 100, and the anchoring member 120 in particular, need not have such a smooth bend.


Referring to FIGS. 9B and 10, the arms 124 are arranged in V-shaped arm units 125 that each have a pair of arms 124 extending from a bifurcation 127 at the base portion 122. In this embodiment, the individual arms 124 in each V-shaped arm unit 125 are separated from each other along their entire length from where they are connected to the base portion 122 through the smooth bend 140 (FIG. 9A) to the structural elements 137 of the fixation structure 130. The individual arms 124 are thus able to readily flex as the edge 708 of the housing 702 (FIG. 7B) slides along the arms 124 during recapturing. This is expected to reduce the likelihood that the edge 708 of the housing 702 will catch on the arms 124 and prevent the device 100 from being recaptured in the housing 702.


In one embodiment, the arms 124 have a first length from the base 122 to the smooth bend 140, and the structural elements 137 of the fixation structure 130 at each side of a cell 138 (FIG. 8) have a second length. The second length of the structural elements 137 along each side of a cell 138 is less than the first length of the arms 124. The fixation structure 130 is accordingly less flexible than the arms 124. As a result, the fixation structure 130 is able to press outwardly against the native annulus with sufficient force to secure the device 100 to the native annulus, while the arms 124 are sufficiently flexible to fold inwardly when the device is recaptured in a delivery device.


In the embodiment illustrated in FIGS. 8-10, the arms 124 and the structural elements 137 are configured such that each arm 124 and the two structural elements 137 extending from each arm 124 formed a Y-shaped portion 142 (FIG. 10) of the anchoring member 120. Additionally, the right-hand structural element 137 of each Y-shaped portion 142 is coupled directly to a left-hand structural element 137 of an immediately adjacent Y-shaped portion 142. The Y-shaped portions 142 and the smooth bends 140 are expected to further enhance the ability to slide the housing 702 along the arms 124 and the fixation structure 130 during recapturing.



FIG. 11 is a side view and FIG. 12A is a bottom isometric view of a prosthetic heart valve device (“device”) 200 in accordance with another embodiment of the present technology. The device 200 is shown without the extension member 170 (FIGS. 8-10), but the device 200 can further include the extension member 170 described above. The base 122 of the device 200 shown in FIG. 12A further includes only a single row of chevron-supports 216 as opposed to the dual-rows of chevron-supports at the base 122 of the device 100 shown in FIG. 10. The device 200 further includes extended connectors 210 projecting from the base 122 of the anchoring member 120. Alternatively, the extended connectors 210 can extend from the valve support 110 (FIGS. 6A-10) in addition to or in lieu of extending from the base 122 of the anchoring member 120. The extended connectors 210 can include a first strut 212a attached to one portion of the base 122 and a second strut 212b attached to another portion of the base 122. The first and second struts 212a-b are configured to form a V-shaped structure in which they extend toward each other in a downstream direction and are connected to each other at the bottom of the V-shaped structure. The V-shaped structure of the first and second struts 212a-b causes the extension connector 210 to elongate when the device 200 is in a low-profile configuration within the capsule 700 (FIG. 7A) during delivery or partial deployment. When the device 200 is fully released from the capsule 700 (FIG. 7A) the extension connectors 210 foreshorten to avoid interfering with blood flow along the left ventricular outflow tract.


The extended connectors 210 further include an attachment element 214 configured to releasably engage a delivery device. The attachment element 214 can be a T-bar or other element that prevents the device 200 from being released from the capsule 700 (FIG. 7A) of a delivery device until desired. For example, a T-bar type attachment element 214 can prevent the device 200 from moving axially during deployment or partial deployment until the housing 702 (FIG. 7A) moves distally beyond the attachment elements 214 such that the outflow region of the valve support 110 and the base 122 of the anchoring member 120 can fully expand upon full deployment.



FIG. 12B is an isometric view of a prosthetic heart valve device 200a (“device 200a”) in accordance with another embodiment of the present technology, and FIG. 12C is a detailed view of an arm unit of the device 200a. The device 200a is substantially similar to the device 200 shown in FIG. 12A, but the device 200a includes a plurality of Y-shaped arm units 224 instead of V-shaped arm units. Referring to FIG. 12C, the arm units 224 have a trunk 226 and two arms 228 extending from the trunk 226 at a bifurcation 227. The trunk 226 of each Y-shaped arm unit 224 extends from a single row of chevron-supports 216 at the base 122 of the anchoring member 120, and the trunks 226 have a length such that the bifurcations 227 are located a distance apart from the base 122. The arms 228 of the Y-shaped arm units 224 can be slightly shorter than the arms 124 of the V-shaped arm units 125 described above with respect to FIG. 9B, but the overall lengths of the Y-shaped and V-shaped arm units 224 and 125 can be about the same. The Y-shaped arm units 224 reduce the amount of metal in the region of the chevron-supports 216 compared to the V-shaped arm units 125, which reduces the material at the base 122 of the anchoring member 120 so that the device 200a can be crimped to a smaller diameter for delivery. Moreover, the Y-shaped arm units 224 are also sufficiently flexible so that the device 200a can be resheathed in a capsule of a delivery device. FIG. 13 is a side view and FIG. 14 is a bottom isometric view of the device 200 in a partially deployed state in which the device 200 is still capable of being recaptured in the housing 702 of the delivery device 700. Referring to FIG. 13, the device 200 is partially deployed with the fixation structure 130 substantially expanded but the attachment elements 214 (FIG. 11) still retained within the capsule 700. This is useful for determining the accuracy of the position of the device 200 and allowing blood to flow through the functioning replacement valve during implantation while retaining the ability to recapture the device 200 in case it needs to be repositioned or removed from the patient. In this state of partial deployment, the elongated first and second struts 212a-b of the extended connectors 210 space the base 122 of the anchoring member 120 and the outflow region of the valve support 110 (FIG. 6A) apart from the edge 708 of the capsule 702 by a gap G.


Referring to FIG. 14, the gap G enables blood to flow through the prosthetic valve assembly 150 while the device 200 is only partially deployed. As a result, the device 200 can be partially deployed to determine (a) whether the device 200 is positioned correctly with respect to the native heart valve anatomy and (b) whether proper blood flow passes through the prosthetic valve assembly 150 while the device 200 is still retained by the delivery system 700. As such, the device 200 can be recaptured if it is not in the desired location and/or if the prosthetic valve is not functioning properly. This additional functionality is expected to significantly enhance the ability to properly position the device 200 and assess, in vivo, whether the device 200 will operate as intended, while retaining the ability to reposition the device 200 for redeployment or remove the device 200 from the patient.



FIG. 15 is a bottom isometric view of a valve support 300 in accordance with an embodiment of the present technology. The valve support 300 can be an embodiment of the valve support 110 described above with respect to FIGS. 6A-14. The valve support 300 has an outflow region 302, an inflow region 304, a first row 310 of first hexagonal cells 312 at the outflow region 302, and a second row 320 of second hexagonal cells 322 at the inflow region 304. The valve support shown in FIG. 15 is inverted compared to the valve support 100 shown in FIGS. 6A-14 for purposes of illustration such that the blood flows through the valve support 300 in the direction of arrow BF. In mitral valve applications, the valve support 300 would be positioned within the anchoring member 120 (FIG. 6A) such that the inflow region 304 would correspond to orientation of the inflow region 112 in FIG. 6A and the outflow region 302 would correspond to the orientation of the outflow region 114 in FIG. 6A.


Each of the first hexagonal cells 312 includes a pair of first longitudinal supports 314, a downstream apex 315, and an upstream apex 316. Each of the second hexagonal cells 322 can include a pair of second longitudinal supports 324, a downstream apex 325, and an upstream apex 326. The first and second rows 310 and 320 of the first and second hexagonal cells 312 and 322 are directly adjacent to each other. In the illustrated embodiment, the first longitudinal supports 314 extend directly from the downstream apexes 325 of the second hexagonal cells 322, and the second longitudinal supports 324 extend directly from the upstream apexes 316 of the first hexagonal cells 312. As a result, the first hexagonal cells 312 are offset circumferentially from the second hexagonal cells 322 around the circumference of the valve support 300 by half of the cell width.


In the embodiment illustrated in FIG. 15, the valve support 300 includes a plurality of first struts 331 at the outflow region 302, a plurality of second struts 332 at the inflow region 304, and a plurality of third struts 333. Each of the first struts 331 extends from a downstream end of the first longitudinal supports 314, and pairs of the first struts 331 are connected together to form first downstream V-struts defining the downstream apexes 315 of the first hexagonal cells 312. In a related sense, each of the second struts 332 extends from an upstream end of the second longitudinal supports 324, and pairs of the second struts 332 are connected together to form second upstream V-struts defining the upstream apexes 326 of the second hexagonal cells 322. Each of the third struts 333 has a downstream end connected to an upstream end of the first longitudinal supports 314, and each of the third struts 333 has an upstream end connected to a downstream end of one of the second longitudinal supports 324. The downstream ends of the third struts 333 accordingly define a second downstream V-strut arrangement that forms the downstream apexes 325 of the second hexagonal cells 322, and the upstream ends of the third struts 333 define a first upstream V-strut arrangement that forms the upstream apexes 316 of the first hexagonal cells 312. The third struts 333, therefore, define both the first upstream V-struts of the first hexagonal cells 312 and the second downstream V-struts of the second hexagonal cells 322.


The first longitudinal supports 314 can include a plurality of holes 336 through which sutures can pass to attach a prosthetic valve assembly and/or a sealing member. In the embodiment illustrated in FIG. 15, only the first longitudinal supports 314 have holes 336. However, in other embodiments the second longitudinal supports 324 can also include holes either in addition to or in lieu of the holes 336 in the first longitudinal supports 314.



FIG. 16 is a side view and FIG. 17 is a bottom isometric view of the valve support 300 with a first sealing member 162 attached to the valve support 300 and a prosthetic valve 150 within the valve support 300. The first sealing member 162 can be attached to the valve support 300 by a plurality of sutures 360 coupled to the first longitudinal supports 314 and the second longitudinal supports 324. At least some of the sutures 360 coupled to the first longitudinal supports 314 pass through the holes 336 to further secure the first sealing member 162 to the valve support 300. Sutures 360 can also pass through the holes 336 if holes 336 are included in addition to or in lieu of the holes 336 of the first longitudinal supports 314.


Referring to FIG. 17, the prosthetic valve 150 can be attached to the first sealing member 162 and/or the first longitudinal supports 314 of the valve support 300. For example, the commissure portions of the prosthetic valve 150 can be aligned with the first longitudinal supports 314, and the sutures 360 can pass through both the commissure portions of the prosthetic valve 150 and the first sealing member 162 where the commissure portions of the prosthetic valve 150 are aligned with a first longitudinal support 314. The inflow portion of the prosthetic valve 150 can be sewn to the first sealing member 162.


The valve support 300 illustrated in FIGS. 15-17 is expected to be well suited for use with the device 100 and 200 and described above with reference to FIGS. 8-10 and 11-14, respectively. More specifically, the first struts 331 cooperate with the base of the anchoring member 122. The first struts 331, for example, elongate when the valve support 300 is not fully expanded compared to when the valve support is fully expanded. In addition to the elongation of the struts, the position of the prosthetic valve 150 within the valve support 300 allows the outflow portion of the prosthetic valve 150 to be spaced further apart from the capsule 700 in a partially deployed state so that the prosthetic valve 150 can at least partially function in the partially deployed state. Alternatively, if attached to the device 200, the extended connectors 210 (FIGS. 11-14) of the device 200 serve to further separate the outflow portion of the prosthetic valve 150 from the capsule 700 (FIGS. 13-14) when the device 200 is in a partially deployed state, allowing for partial function of the prosthetic valve 150. Upon full deployment, the first struts 331 foreshorten. Therefore, the valve support 300 is expected to enhance the ability to assess whether the prosthetic valve 150 is fully operational in a partially deployed state. This additional functionality is expected to significantly enhance the ability to assess, in vivo, whether the device 100 and 200 will operate as intended, while retaining the ability to reposition the device 100 and 200 for redeployment or remove the device 100 and 200 from the patient.



FIGS. 18 and 19 are schematic side views of valve supports 400 and 500, respectively, in accordance with embodiments of the present technology. The valve support 400 includes a first row 410 of first of hexagonal cells 412 and a second row 420 of second hexagonal cells 422. The valve 400 can further include a first row 430 of diamond-shaped cells extending from the first hexagonal cells 412 and a second row 440 of diamond-shaped cells extending from the second hexagonal cells 422. The additional diamond-shaped cells elongate in the low-profile state, and thus they can further space the prosthetic valve 150 (shown schematically) apart from the capsule of the delivery device, enhancing the ability to assess, in vivo, whether the device will operate as intended while retaining the ability to reposition or remove the device from the patient. Referring to FIG. 19, the valve support 500 includes a first row 510 of first hexagonal cells 512 at an outflow region 502 and a second row 520 of second hexagonal cells 522 at an inflow region 504. The valve support 500 is shaped such that an intermediate region 506 has a smaller cross-sectional area than that of the outflow region 502 and/or the inflow region 504. As such, the first row 510 of first hexagonal cells 512 flares outwardly in the downstream direction and the second row 520 of second hexagonal cells 522 flares outwardly in the upstream direction. The flared outflow and inflow regions 502 and 504 are expected to improve blood flow through the valve support 500. Additionally, the flared outflow and inflow regions 502 and 504 reduce the length of the valve support compared to a straight cylindrical design, which reduces the amount that the valve support 500 extends into the left ventricle.



FIG. 20 is a schematic view showing a portion of an anchoring member 120 in accordance with an embodiment of the present technology. In this embodiment, the anchoring member 120 includes the fixation structure 130 and V-shaped arm units 620 (only a single arm unit shown). Each V-shaped arm unit 620 includes a pair of arms 622 extending from the base 122 to the fixation structure 130 (only a portion shown), and each arm 622 includes a first portion 624 having a first flexibility and a second portion 626 with a second flexibility less than the first flexibility. The first portion 624 of the arms 622 are selectively flexible at the base 122 of the anchoring member 120, while the second portion 626 of the arms 622 have sufficient stiffness to push the fixation structure 130 radially outwardly for engaging the native annulus. In the illustrated embodiment, the first portion 624 of the arms 622 are a serpentine member (e.g., an according connector), and the second portion 626 of the arms 622 are straighter than the first portion 624. For example the second portion 626 of the arms 622 can curve radially outward along an arc (e.g. a single arc) as opposed to the serpentine or the zig-zag configuration of the first portion 624.



FIG. 21 is a schematic view showing a portion of another anchoring member 120 in accordance with an embodiment of the present technology including Y-shaped arm units 720 (only a single arm unit 720 shown). Each Y-shaped arm unit 720 has a trunk 724 and arms 726 extending from the trunk 724. The trunk 724 has a first flexibility, and the arms 726 have a second flexibility less than the first flexibility. The trunk 724, for example, is a strut having a serpentine configuration (e.g., an accordion connector), and the arms 726 can be curved struts extending radially outward from the trunk 724 in an expanded configuration.



FIG. 22 schematically illustrates the operation of the arm units 620 and 720 shown in FIGS. 20 and 21. In operation, the native annulus (not shown) exerts a compressive annulus force FA against the fixation structure 130 while the systolic pressure creates a force FP. The additional flexibility of the first portion 624 or the trunk 724 allows the arm units 620 and 720 to preferentially flex near the outflow end of the valve support 110 to allow the fixation structure 130 to be deformed by the native annulus while mitigating the commissure forces Fc exerted against the valve support 110 at the base 122. Notably, the second portion 626 of the arms 622 and the arms 726 are sufficiently stiff to provide the desired radially outward force against the native annulus for securing the prosthetic heart valve device at the native heart valve.



FIG. 23 illustrates an arm 800 supporting a fixation structure 130 in accordance with another embodiment of the present technology. The arm 800 can include a first portion 820 configured to be coupled to the outflow region of a valve support and a second portion 822 extending from the first portion 820 to the fixation structure 130. The first portion 820 of the arm 800 can correspond to the first portion 624 of the arms 622 of the V-shaped arm unit 620 or the trunk 724 of the Y-shaped arm unit 720. The first portion 820 of the arm 800 can further include a plurality of outward recesses 824 (e.g., notches) that enable the first portion 822 preferentially flex outward (arrow O). The arm 800 is expected to perform substantially similarly to the arms 622 and the Y-shaped arm unit 720 described above with reference to FIGS. 20-22.



FIGS. 24A and 24B are schematic views showing arms 124 having difference configurations of eyelets 900 for coupling the second sealing member 164 (FIGS. 6A and 6B) to the anchoring member 120. Referring to FIG. 24A, the eyelets 900 are on the outside of the arms 124. Referring to FIG. 24B, the eyelets are on the inside of the arms 124. In both embodiments, sutures 902 pass through the eyelets to attach the second sealing member 164 to the inside of the anchoring member 120. The embodiment shown in FIG. 24B is particularly well-suited for resheathing the prosthetic heart valve devices because the eyelets are shape-set to extend inwardly to eliminate or otherwise limit protrusions relative to the outer surface of the arms 124 that could inhibit the capsule from sliding over the arms 124 during resheathing.


EXAMPLES

Several aspects of the present technology described above are embodied in the following examples.

  • 1. A prosthetic heart valve device for treating a native valve of a human heart having a native annulus and native leaflets, comprising:
    • a valve support having an inflow region and an outflow region;
    • a prosthetic valve assembly within the valve support; and
    • an anchoring member having a base attached to the outflow region of the valve support, a plurality of arms projecting laterally outward from the base and inclined in an upstream direction in a deployed state, and a fixation structure extending upstream from the arms, the fixation structure having a plurality of struts that define an annular engagement surface configured to press outwardly against the native annulus and a plurality of fixation elements projecting from the struts, wherein a downstream-most portion of the fixation structure extends from the arms at a smooth bend and fixation elements at the downstream-most portion of the fixation structure extend in an upstream direction.
  • 2. The prosthetic heart valve device of example 1 wherein the arms are spaced apart from each other throughout their length.
  • 3. The prosthetic heart valve device of any of examples 1-2 wherein the struts of the fixation structure are arranged in cells having sides, and the arms have a first length and each side of the cells has a second length less than the first length.
  • 4. The prosthetic heart valve device of any of examples 1-3 wherein each arm and the struts of the fixation structure extending from each arm form a Y-shaped portion of the anchoring member, and a right-hand strut of each Y-shaped portion is coupled directly to a left-hand strut of an immediately adjacent Y-shaped portion.
  • 5. The prosthetic heart valve device of any of examples 1-4, further comprising connector extensions projecting from a downstream end of the valve support and/or the base, and wherein each connector extension has first and second struts forming a V-shaped structure extending downstream from the valve support and/or the base, and a connector projecting downstream from the V-shaped structure, wherein the connector is configured to be releasably held by a delivery device.
  • 6. The prosthetic heart valve device of any of examples 1-5 wherein all of the fixation elements projecting from the fixation structure extend in an upstream direction.
  • 7. The prosthetic heart valve device of any of examples 1-6 wherein the valve support comprises:
    • a first row of first hexagonal cells at the outflow region of the valve support, and the first hexagonal cells having first longitudinal supports;
    • a second row of second hexagonal cells at the inflow region of the valve support, the second hexagonal cells having second longitudinal supports, wherein the first and second hexagonal cells are directly adjacent to each other such that the first longitudinal supports extend directly from downstream apexes of the second hexagonal cells and the second longitudinal supports extend directly from upstream apexes of the first hexagonal cells; and
    • wherein the prosthetic valve assembly is attached to at least one of the first longitudinal supports and/or at least one of the second longitudinal supports.
  • 8. The prosthetic heart valve device of example 7 wherein the valve support further comprises a first row of diamond-shaped cells at a downstream end of the first row of hexagonal cells and a second row of diamond-shaped cells at an upstream end of the second row of hexagonal cells.
  • 9. The prosthetic heart valve device of example 7 wherein the first row of hexagonal cells flares outward in the downstream direction and the second row of hexagonal cells flares outward in the upstream direction.
  • 10. The prosthetic heart valve device of example 7, further comprising connector extensions projecting from a downstream end of the valve support and/or the base, and wherein each connector extension has first and second struts forming a V-shaped structure extending downstream from the valve support and/or the base, and a connector projecting downstream from the V-shaped structure, wherein the connector is configured to be releasably held by a delivery device.
  • 11. The prosthetic heart valve device of any of examples 1-10 wherein the valve support comprises:
    • a first row of first hexagonal cells at the outflow region of the valve support, wherein the first hexagonal cells have first longitudinal supports, first upstream V-struts extending upstream from the first longitudinal supports, and first downstream V-struts extending downstream from the first longitudinal supports;
    • a second row of second hexagonal cells at the inflow region of the valve support, wherein the second hexagonal cells have second longitudinal supports, second upstream V-struts extending upstream from the second longitudinal supports, and second downstream V-struts extending downstream from the second longitudinal supports; and
    • wherein the first upstream V-struts of the first hexagonal cells and the second downstream inverted V-struts of the second hexagonal cells are the same struts.
  • 12. A prosthetic heart valve device for treating a native valve of a human heart having a native annulus and native leaflets, comprising:
    • an annular inner support frame having an inflow region and an outflow region;
    • a prosthetic valve assembly within the inner support frame; and
    • an anchoring member having a base attached to the outflow region of the inner support frame, a plurality of arms projecting laterally outward from the base at an angle inclined in an upstream direction, and an outer fixation frame extending upstream from the arms, the outer fixation frame having a plurality of struts that define an annular engagement surface spaced radially outward from the inflow region of the inner support frame in the deployed state, wherein the arms and the struts are configured to be partially deployed from a capsule and then at least substantially recaptured within the capsule by moving at least one of the capsule and/or the device relative to the other such the arms and struts slide into the capsule.
  • 13. The prosthetic heart valve device of example 12 wherein the arms are spaced apart from each other throughout their length.
  • 14. The prosthetic heart valve device of any of examples 12-13 wherein the struts of the outer fixation frame are arranged in cells having sides, and the arms have a first length and each side of the cells has a second length less than the first length.
  • 15. The prosthetic heart valve device of any of examples 12-14 wherein each arm and the struts of the outer fixation frame extending from each arm form a Y-shaped portion of the anchoring member, and a right-hand strut of each Y-shaped portion is coupled directly to a left-hand strut of an immediately adjacent Y-shaped portion.
  • 16. The prosthetic heart valve device of any of examples 12-15, further comprising connector extensions projecting from a downstream end of the inner annular support frame and/or the base, and wherein each connector extension has first and second struts forming a V-shaped structure extending downstream from the inner annular support frame and/or the base, and a connector projecting downstream from the V-shaped structure, wherein the connector is configured to be releasably held by a delivery device.
  • 17. The prosthetic heart valve device of any of examples 12-16, further comprising fixation elements projecting from the outer fixation frame, and wherein all of the fixation elements project from the outer fixation frame extend in an upstream direction.
  • 18. The prosthetic heart valve device of any of examples 12-17 wherein the inner annular support frame comprises:
    • a first row of first hexagonal cells at the outflow region of the inner annular support frame, and the first hexagonal cells having first longitudinal supports;
    • a second row of second hexagonal cells at the inflow region of the inner annular support frame, the second hexagonal cells having second longitudinal supports, wherein the first and second hexagonal cells are directly adjacent to each other such that the first longitudinal supports extend directly from downstream apexes of the second hexagonal cells and the second longitudinal supports extend directly from upstream apexes of the first hexagonal cells; and
    • wherein the prosthetic valve assembly is attached to at least one of the first longitudinal supports and/or at least one of the second longitudinal supports.
  • 19. The prosthetic heart valve device of example 18 wherein the inner annular support frame further comprises a first row of diamond-shaped cells at a downstream end of the first row of hexagonal cells and a second row of diamond-shaped cells at an upstream end of the second row of hexagonal cells.
  • 20. The prosthetic heart valve device of example 18 wherein the first row of hexagonal cells flares outward in the downstream direction and the second row of hexagonal cells flares outward in the upstream direction.
  • 21. The prosthetic heart valve device of example 18, further comprising connector extensions projecting from a downstream end of the inner annular support frame and/or the base, and wherein each connector extension has first and second struts forming a V-shaped structure extending downstream from the inner annular support frame and/or the base, and a connector projecting downstream from the V-shaped structure, wherein the connector is configured to be releasably held by a delivery device.
  • 22. The prosthetic heart valve device of any of examples 1-21 wherein the arms are arranged in pairs defining V-shaped arm units.
  • 23. The prosthetic heart valve device of example 22 wherein the V-shaped arm units have a pair of arm, and each arm has a first portion having a first flexibility and a second portion having a second flexibility less than the first flexibility.
  • 24. The prosthetic heart valve device of example 23 wherein the first portion has a serpentine configuration.
  • 25. the prosthetic heart valve device of example 23 wherein the first portion has outwardly open notches.
  • 26. The prosthetic heart valve device of any of examples 1, 3-12 and 14-21 wherein the arms are arranged in Y-shaped arm units having a trunk and a pair of arms extending from the trunk.
  • 27. The prosthetic heart valve device of examples 26 wherein the trunk has a first flexibility and the arms have a second flexibility less than the first flexibility.
  • 28. The prosthetic heart valve device of example 27 wherein the trunk has a serpentine configuration.
  • 29. The prosthetic heart valve device of example 27 wherein the trunk has a plurality of outwardly open notches.
  • 30. A method of deploying a prosthetic heart valve device for treating a native heart valve, comprising:
    • partially deploying a prosthetic heart valve device from a capsule of a delivery device such that an inflow region of a valve support and an inflow region of a fixation structure are expanded radially outward relative to the capsule with the inflow region of the fixation structure being spaced radially outward of the valve support, wherein an outflow region of the valve support and/or the fixation structure remains within the capsule, and wherein a gap exists between a downstream end of a prosthetic valve within the valve support and a distal terminus of the capsule such that fluid can flow through the valve while the outflow region is within the capsule; and
    • recapturing the prosthetic heart valve device within the capsule.
  • 31. The method of example 30 wherein the native heart valve is a native mitral valve.
  • 32. The method of example 30 wherein the native heart valve is a native aortic valve.
  • 33. A valve support for a prosthetic heart valve, comprising:
    • a first row of first hexagonal cells at an outflow region of the valve support, wherein the first hexagonal cells have first longitudinal supports, first and second upstream struts extending upstream from the first longitudinal supports, and first and second downstream struts extending downstream from the first longitudinal supports;
    • a second row of second hexagonal cells at an inflow region of the valve support, wherein the second hexagonal cells have second longitudinal supports, first and second upstream struts extending upstream from the second longitudinal supports, and first and second downstream struts extending downstream from the second longitudinal supports; and
    • wherein the first and second upstream struts of the first hexagonal cells and the first and second downstream struts of the second hexagonal cells are the same struts.
  • 34. The valve support of example 33 wherein the first and second longitudinal supports have a first width and the first and second upstream struts and the first and second downstream struts have a second width less than the first width.
  • 35. The valve support of any of examples 33-34 wherein:
    • the first and second hexagonal cells are directly adjacent to each other such that the first longitudinal supports extend directly from downstream apexes of the second hexagonal cells and the second longitudinal supports extend directly from upstream apexes of the first hexagonal cells; and
    • wherein the prosthetic valve assembly is attached to at least one of the first longitudinal supports and/or at least one of the second longitudinal supports.
  • 36. The prosthetic heart valve device of any of examples 33-35 wherein the valve support further comprises a first row of diamond-shaped cells at a downstream end of the first row of hexagonal cells and a second row of diamond-shaped cells at an upstream end of the second row of hexagonal cells.
  • 37. The prosthetic heart valve device of any of examples 33-36 wherein the first row of hexagonal cells flares outward in the downstream direction and the second row of hexagonal cells flares outward in the upstream direction.
  • 38. The prosthetic heart valve device of any of examples 33-37, further comprising connector extensions projecting from a downstream end of the first hexagonal cells, and wherein each connector extension has first and second struts forming a V-shaped structure extending downstream from the first hexagonal cells, and a connector projecting downstream from the V-shaped structure, wherein the connector is configured to be releasably held by a delivery device.


From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the scope of the invention. For example, several individual components can be interchange with each other in the different embodiments. Accordingly, the invention is not limited except as by the appended claims.

Claims
  • 1. A method comprising: positioning a capsule of a delivery device proximate a native heart valve;partially deploying a prosthetic heart valve device from the capsule of the delivery device such that an inflow region of a valve support and an inflow region of a fixation structure are expanded radially outward relative to the capsule with the inflow region of the fixation structure being spaced radially outward of the valve support, wherein a portion of the prosthetic heart valve device remains disposed within the capsule of the delivery device while a gap exists between a downstream end of a prosthetic valve at an outflow region of the valve support and a distal terminus of the capsule such that fluid can flow through the prosthetic valve while the portion of the prosthetic heart valve device remains within the capsule of the delivery device, wherein the prosthetic valve is within the valve support; andrecapturing the prosthetic heart valve device within the capsule.
  • 2. The method of claim 1, wherein the native heart valve is a native mitral valve.
  • 3. The method of claim 1, wherein the native heart valve is a native aortic valve.
  • 4. The method of claim 1, wherein the prosthetic heart valve device further comprises arms coupled to the outflow region of the valve support and the fixation structure extends from the arms along a smooth bend, and wherein recapturing the prosthetic heart valve device within the capsule comprises holding a downstream end of the prosthetic heart valve device while sliding the capsule over the arms and the smooth bend.
  • 5. The method of claim 1, wherein the gap is formed by connector extensions extending in a downstream direction with respect to the outflow region of the valve support.
  • 6. The method of claim 1, wherein the prosthetic heart valve device comprises: a plurality of arms configured to project laterally outward from the outflow region of the valve support and be inclined in an upstream direction in a deployed state, wherein the fixation structure is configured to extend upstream from the plurality of arms.
  • 7. The method of claim 6, wherein the fixation structure comprises a plurality of struts that define an annular engagement surface configured to press outwardly against the native heart valve and a plurality of fixation elements projecting from the struts.
  • 8. The method of claim 7, wherein a downstream-most portion of the fixation structure is configured to extend from the plurality of arms at a smooth bend, and wherein all of the fixation elements project from the fixation structure in an upstream direction.
  • 9. The method of claim 8, wherein the plurality of arms, the plurality of struts, and the plurality of fixation elements are configured to be at least partially deployed from the capsule and then at least substantially recaptured within the capsule.
  • 10. A method comprising: positioning a capsule of a delivery device proximate a native heart valve;partially deploying a prosthetic heart valve device from the capsule of the delivery device such that an inflow region of a valve support and an inflow region of a fixation structure are expanded radially outward relative to the capsule with the inflow region of the fixation structure being spaced radially outward of the valve support, wherein a portion of the prosthetic heart valve device remains coupled to the delivery device while a gap exists between a downstream end of a prosthetic valve at an outflow region of the valve support and a distal terminus of the capsule such that fluid can flow through the prosthetic valve while the prosthetic heart valve device remains coupled to the delivery device, wherein the prosthetic valve is within the valve support; andrecapturing the prosthetic heart valve device within the capsule,wherein the prosthetic heart valve device comprises a plurality of arms configured to project laterally outward from the outflow region of the valve support and be inclined in an upstream direction in a deployed state, wherein the fixation structure is configured to extend upstream from the plurality of arms,wherein the fixation structure comprises a plurality of struts that define an annular engagement surface configured to press outwardly against the native heart valve and a plurality of fixation elements projecting from the struts, andwherein each arm of the plurality of arms and the struts of the fixation structure extending from each arm form a Y-shaped portion, and a right-hand strut of each Y-shaped portion is coupled directly to a left-hand strut of an immediately adjacent Y-shaped portion.
  • 11. A method comprising: positioning a capsule of a delivery device proximate a native heart valve;partially deploying a prosthetic heart valve device from the capsule of the delivery device such that an inflow region of a valve support and an inflow region of a fixation structure are expanded radially outward relative to the capsule with the inflow region of the fixation structure being spaced radially outward of the valve support, wherein a portion of the prosthetic heart valve device remains coupled to the delivery device while a gap exists between a downstream end of a prosthetic valve at an outflow region of the valve support and a distal terminus of the capsule such that fluid can flow through the prosthetic valve while the prosthetic heart valve device remains coupled to the delivery device, wherein the prosthetic valve is within the valve support; andrecapturing the prosthetic heart valve device within the capsule,wherein the valve support comprises: a first row of first hexagonal cells at the outflow region of the valve support, and the first hexagonal cells having first longitudinal supports;a second row of second hexagonal cells at the inflow region of the valve support, the second hexagonal cells having second longitudinal supports, wherein the first and second hexagonal cells are directly adjacent to each other such that the first longitudinal supports extend directly from downstream apexes of the second hexagonal cells and the second longitudinal supports extend directly from upstream apexes of the first hexagonal cells; andwherein the prosthetic valve assembly is attached to at least one of the first longitudinal supports and/or at least one of the second longitudinal supports.
  • 12. The method of claim 11, wherein the valve support further comprises a first row of diamond-shaped cells at a downstream end of the first row of hexagonal cells and a second row of diamond-shaped cells at an upstream end of the second row of hexagonal cells.
  • 13. The method of claim 11, wherein the first row of hexagonal cells flares outward in a downstream direction and the second row of hexagonal cells flares outward in an upstream direction.
  • 14. The method of claim 11, further comprising connector extensions projecting from a downstream end of the valve support, and wherein each connector extension has first and second struts forming a V-shaped structure extending downstream from the valve support, and a connector projecting downstream from the V-shaped structure, wherein the connector is configured to be releasably held by the delivery device.
Parent Case Info

This application is a divisional of U.S. patent application Ser. No. 15/490,047, filed Apr. 18, 2017. The entire contents of application Ser. No. 15/490,047 is incorporated herein by reference.

US Referenced Citations (838)
Number Name Date Kind
3229736 Klienschrodt Jan 1966 A
3245980 Stright Apr 1966 A
3250154 Breuning May 1966 A
3256077 Abler Jun 1966 A
3258883 Campanaro et al. Jul 1966 A
3273910 Willingshofer et al. Sep 1966 A
3526219 Balamuth Sep 1970 A
3565062 Kuris Feb 1971 A
3589363 Banko et al. Jun 1971 A
3667474 Lapkin et al. Jun 1972 A
3823717 Pohlman et al. Jul 1974 A
3861391 Antonevich et al. Jan 1975 A
3896811 Storz Jul 1975 A
4042979 Angell Aug 1977 A
4188952 Loschilov et al. Feb 1980 A
4388735 Ionescu et al. Jun 1983 A
4423525 Vallana et al. Jan 1984 A
4431006 Trimmer et al. Feb 1984 A
4441216 Ionescu et al. Apr 1984 A
4445509 Auth May 1984 A
4484579 Meno et al. Nov 1984 A
4490859 Black et al. Jan 1985 A
4587958 Noguchi et al. May 1986 A
4589419 Laughlin et al. May 1986 A
4602911 Ahmadi et al. Jul 1986 A
4629459 Ionescu et al. Dec 1986 A
4646736 Auth Mar 1987 A
4653577 Noda Mar 1987 A
4666442 Arru et al. May 1987 A
4679556 Lubock et al. Jul 1987 A
4692139 Stiles Sep 1987 A
4747821 Kensey et al. May 1988 A
4750902 Wuchinich et al. Jun 1988 A
4758151 Arru et al. Jul 1988 A
4777951 Cribier et al. Oct 1988 A
4787388 Hofmann Nov 1988 A
4796629 Grayzel Jan 1989 A
4808153 Parisi Feb 1989 A
4819751 Shimada et al. Apr 1989 A
4841977 Griffith et al. Jun 1989 A
4870953 DonMicheal et al. Oct 1989 A
4878495 Grayzel Nov 1989 A
4892540 Vallana Jan 1990 A
4898575 Fischell et al. Feb 1990 A
4909252 Goldberger Mar 1990 A
4919133 Chiang Apr 1990 A
4920954 Alliger et al. May 1990 A
4936281 Stasz Jun 1990 A
4960411 Buchbinder Oct 1990 A
4960424 Grooters Oct 1990 A
4986830 Owens et al. Jan 1991 A
4990134 Auth Feb 1991 A
5002567 Bona et al. Mar 1991 A
5058570 Idemoto et al. Oct 1991 A
5069664 Guess et al. Dec 1991 A
5076276 Sakurai et al. Dec 1991 A
5084151 Vallana et al. Jan 1992 A
5104406 Curcio et al. Apr 1992 A
5106302 Farzin-Nia et al. Apr 1992 A
5248296 Alliger Sep 1993 A
5267954 Nita Dec 1993 A
5269291 Carter Dec 1993 A
5295958 Shturman Mar 1994 A
5304115 Pflueger et al. Apr 1994 A
5314407 Auth et al. May 1994 A
5318014 Carter Jun 1994 A
5332402 Teitelbaum Jul 1994 A
5344426 Lau et al. Sep 1994 A
5344442 Deac Sep 1994 A
5352199 Tower Oct 1994 A
5356418 Shturman Oct 1994 A
5370684 Vallana et al. Dec 1994 A
5387247 Vallana et al. Feb 1995 A
5397293 Alliger et al. Mar 1995 A
5411552 Andersen et al. May 1995 A
5443446 Shturman Aug 1995 A
5449373 Pinchasik et al. Sep 1995 A
5489297 Duran Feb 1996 A
5584879 Reimold et al. Dec 1996 A
5609151 Mulier et al. Mar 1997 A
5626603 Venturelli et al. May 1997 A
5656036 Palmaz Aug 1997 A
5662671 Barbut et al. Sep 1997 A
5662704 Gross et al. Sep 1997 A
5681336 Clement et al. Oct 1997 A
5695507 Auth et al. Dec 1997 A
5713953 Vallana et al. Feb 1998 A
5725494 Brisken Mar 1998 A
5782931 Yang et al. Jul 1998 A
5817101 Fiedler Oct 1998 A
5827229 Auth et al. Oct 1998 A
5827321 Roubin et al. Oct 1998 A
5840081 Andersen et al. Nov 1998 A
5853422 Huebsch et al. Dec 1998 A
5855601 Bessler et al. Jan 1999 A
5868781 Killion Feb 1999 A
5873811 Wang et al. Feb 1999 A
5873812 Ciana et al. Feb 1999 A
5904679 Clayman May 1999 A
5957882 Nita et al. Sep 1999 A
5972004 Williamson, IV et al. Oct 1999 A
5989208 Nita Nov 1999 A
5989280 Euteneuer et al. Nov 1999 A
6047700 Eggers et al. Apr 2000 A
6056759 Fiedler May 2000 A
6085754 Alfemess et al. Jul 2000 A
6113608 Monroe et al. Sep 2000 A
RE36939 Tachibana et al. Oct 2000 E
6129734 Shturman et al. Oct 2000 A
6132444 Shturman et al. Oct 2000 A
6168579 Tsugita Jan 2001 B1
6217595 Shturman et al. Apr 2001 B1
6254635 Schroeder et al. Jul 2001 B1
6295712 Shturman et al. Oct 2001 B1
6306414 Koike Oct 2001 B1
6321109 Ben-Haim et al. Nov 2001 B2
6402679 Mortier et al. Jun 2002 B1
6423032 Parodi Jul 2002 B2
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454737 Nita et al. Sep 2002 B1
6454757 Nita et al. Sep 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6494890 Shturman et al. Dec 2002 B1
6494891 Cornish et al. Dec 2002 B1
6505080 Sutton Jan 2003 B1
6530952 Vesely Mar 2003 B2
6540782 Snyders Apr 2003 B1
6562067 Mathis May 2003 B2
6565588 Clement et al. May 2003 B1
6569196 Vesely May 2003 B1
6579308 Jansen et al. Jun 2003 B1
6582462 Andersen et al. Jun 2003 B1
6595912 Lau et al. Jul 2003 B2
6605109 Fiedler Aug 2003 B2
6616689 Ainsworth et al. Sep 2003 B1
6623452 Chien et al. Sep 2003 B2
6638288 Shturman et al. Oct 2003 B1
6648854 Patterson et al. Nov 2003 B1
6689086 Nita et al. Feb 2004 B1
6702748 Nita et al. Mar 2004 B1
6730121 Ortiz et al. May 2004 B2
6746463 Schwartz Jun 2004 B1
6811801 Nguyen et al. Nov 2004 B2
6818001 Wulfman et al. Nov 2004 B2
6843797 Nash et al. Jan 2005 B2
6852118 Shturman et al. Feb 2005 B2
6855123 Nita Feb 2005 B2
6869439 White et al. Mar 2005 B2
6951571 Srivastava Oct 2005 B1
6986775 Morales et al. Jan 2006 B2
7018404 Holmberg et al. Mar 2006 B2
7052487 Cohn et al. May 2006 B2
7077861 Spence Jul 2006 B2
7125420 Rourke et al. Oct 2006 B2
7186264 Liddicoat et al. Mar 2007 B2
7220277 Arru et al. May 2007 B2
7261732 Justino Aug 2007 B2
7296577 Lashinski et al. Nov 2007 B2
7381218 Schreck Jun 2008 B2
7404824 Webler et al. Jul 2008 B1
7442204 Schwammenthal et al. Oct 2008 B2
7473275 Marquez Jan 2009 B2
7510574 Le et al. Mar 2009 B2
7510575 Spenser et al. Mar 2009 B2
7585321 Cribier Sep 2009 B2
7588582 Starksen et al. Sep 2009 B2
7621948 Herrmann et al. Nov 2009 B2
7708775 Rowe et al. May 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7753922 Starksen Jul 2010 B2
7753949 Lamphere et al. Jul 2010 B2
7803168 Gifford et al. Sep 2010 B2
7857845 Stacchino et al. Dec 2010 B2
7896915 Guyenot et al. Mar 2011 B2
7942928 Webler et al. May 2011 B2
7993392 Righini et al. Aug 2011 B2
8002826 Seguin Aug 2011 B2
8006535 Righini et al. Aug 2011 B2
8034103 Burriesci et al. Oct 2011 B2
8052750 Tuval et al. Nov 2011 B2
8057539 Ghione et al. Nov 2011 B2
8062355 Figulla et al. Nov 2011 B2
8070799 Righini et al. Dec 2011 B2
8109996 Stacchino et al. Feb 2012 B2
8114154 Righini et al. Feb 2012 B2
8226711 Mortier et al. Jul 2012 B2
8252051 Chau et al. Aug 2012 B2
8353953 Giannetti et al. Jan 2013 B2
8398704 Straubinger et al. Mar 2013 B2
8403981 Forster et al. Mar 2013 B2
8403982 Giannetti et al. Mar 2013 B2
8403983 Quadri et al. Mar 2013 B2
8414643 Tuval et al. Apr 2013 B2
8449599 Chau et al. May 2013 B2
8470024 Ghione et al. Jun 2013 B2
8486137 Suri et al. Jun 2013 B2
8475521 Suri et al. Jul 2013 B2
8496671 Hausen Jul 2013 B1
8512252 Ludomirsky et al. Aug 2013 B2
8512397 Rolando et al. Aug 2013 B2
8518107 Tsukashima et al. Aug 2013 B2
8523883 Saadat Sep 2013 B2
8532352 Ionasec et al. Sep 2013 B2
8539662 Stacchino et al. Sep 2013 B2
8540767 Zhang Sep 2013 B2
8540768 Stacchino et al. Sep 2013 B2
8545551 Loulmet Oct 2013 B2
8551161 Dolan Oct 2013 B2
8579788 Orejola Nov 2013 B2
8579964 Lane et al. Nov 2013 B2
8585755 Chau et al. Nov 2013 B2
8597347 Maurer et al. Dec 2013 B2
8597348 Rowe et al. Dec 2013 B2
8608796 Matheny Dec 2013 B2
8608797 Gross et al. Dec 2013 B2
8623077 Cohn Jan 2014 B2
8628566 Eberhardt et al. Jan 2014 B2
8632585 Seguin et al. Jan 2014 B2
8632586 Spenser et al. Jan 2014 B2
8634935 Gaudiani Jan 2014 B2
8647254 Callas et al. Feb 2014 B2
8652203 Quadri et al. Feb 2014 B2
8652204 Quill et al. Feb 2014 B2
8657872 Seguin Feb 2014 B2
8672998 Lichtenstein et al. Mar 2014 B2
8673001 Cartledge et al. Mar 2014 B2
8679176 Matheny Mar 2014 B2
8685086 Navia et al. Apr 2014 B2
8688234 Zhu et al. Apr 2014 B2
8690858 Machold et al. Apr 2014 B2
8709074 Solem et al. Apr 2014 B2
8712133 Guhring et al. Apr 2014 B2
8715160 Raman et al. May 2014 B2
8715207 Righini et al. May 2014 B2
8721665 Oz et al. May 2014 B2
8721718 Kassab May 2014 B2
8740918 Seguin Jun 2014 B2
8747460 Tuval et al. Jun 2014 B2
8758431 Orlov et al. Jun 2014 B2
8758432 Solem Jun 2014 B2
8771292 Allen et al. Jul 2014 B2
8771345 Tuval et al. Jul 2014 B2
8771346 Tuval et al. Jul 2014 B2
8777991 Zarbatany et al. Jul 2014 B2
8778016 Janovsky et al. Jul 2014 B2
8781580 Hedberg et al. Jul 2014 B2
8784482 Rahdert et al. Jul 2014 B2
8792699 Guetter et al. Jul 2014 B2
8795356 Quadri et al. Aug 2014 B2
8801779 Seguin et al. Aug 2014 B2
8808356 Braido et al. Aug 2014 B2
8808366 Braido et al. Aug 2014 B2
8808367 Suri et al. Aug 2014 B2
8812431 Voigt et al. Aug 2014 B2
8828043 Chambers Sep 2014 B2
8834563 Righini Sep 2014 B2
8840661 Manasse Sep 2014 B2
8845717 Khairkhahan et al. Sep 2014 B2
8845723 Spence et al. Sep 2014 B2
8852213 Gammie et al. Oct 2014 B2
8852272 Gross et al. Oct 2014 B2
8858622 Machold et al. Oct 2014 B2
8859724 Meier et al. Oct 2014 B2
8864822 Spence et al. Oct 2014 B2
8870936 Rowe Oct 2014 B2
8870948 Erzberger et al. Oct 2014 B1
8870949 Rowe Oct 2014 B2
8888843 Khairkhahan et al. Nov 2014 B2
8894702 Quadri et al. Nov 2014 B2
8900295 Migliazza et al. Dec 2014 B2
8920492 Stacchino et al. Dec 2014 B2
8926694 Costello Jan 2015 B2
8932348 Solem et al. Jan 2015 B2
8951285 Sugimoto et al. Feb 2015 B2
8961597 Subramanian et al. Feb 2015 B2
8968393 Rothstein Mar 2015 B2
8968395 Hauser et al. Mar 2015 B2
8974445 Warnking et al. Mar 2015 B2
8979922 Jayasinghe et al. Mar 2015 B2
8979923 Spence et al. Mar 2015 B2
8986329 Seguin et al. Mar 2015 B2
8986370 Annest Mar 2015 B2
8986376 Solem Mar 2015 B2
8992604 Gross et al. Mar 2015 B2
9011522 Annest Apr 2015 B2
9011523 Seguin Apr 2015 B2
9017399 Gross et al. Apr 2015 B2
9023098 Kuehn May 2015 B2
9023100 Quadri et al. May 2015 B2
9050188 Schweich, Jr. et al. Jun 2015 B2
9056008 Righini et al. Jun 2015 B2
9066800 Clague et al. Jun 2015 B2
9078749 Lutter et al. Jul 2015 B2
9084676 Chau et al. Jul 2015 B2
9095433 Lutter et al. Aug 2015 B2
9114010 Gaschino et al. Aug 2015 B2
9119713 Board et al. Sep 2015 B2
9125742 Yoganathan et al. Sep 2015 B2
9132009 Hacohen et al. Sep 2015 B2
9138312 Tuval et al. Sep 2015 B2
9138313 McGuckin, Jr. et al. Sep 2015 B2
9138314 Rolando et al. Sep 2015 B2
9149207 Sauter et al. Oct 2015 B2
9161836 Rolando et al. Oct 2015 B2
9168105 Giannetti et al. Oct 2015 B2
9180005 Lashinski et al. Nov 2015 B1
9186249 Rolando et al. Nov 2015 B2
9192466 Kovalsky et al. Nov 2015 B2
9192471 Bolling Nov 2015 B2
9198756 Aklog et al. Dec 2015 B2
9204819 Grunwald et al. Dec 2015 B2
9232942 Seguin et al. Jan 2016 B2
9232999 Maurer et al. Jan 2016 B2
9241790 Lane et al. Jan 2016 B2
9248014 Lane et al. Feb 2016 B2
9248017 Rolando et al. Feb 2016 B2
9254192 Lutter et al. Feb 2016 B2
9271833 Kim et al. Mar 2016 B2
9289289 Rolando et al. Mar 2016 B2
9289291 Gorman, III et al. Mar 2016 B2
9289297 Wilson et al. Mar 2016 B2
9295547 Costello et al. Mar 2016 B2
9301836 Buchbinder et al. Apr 2016 B2
9308087 Lane et al. Apr 2016 B2
9326850 Venkatasubramanian May 2016 B2
9339207 Grunwald et al. May 2016 B2
9339378 Quadri et al. May 2016 B2
9339379 Quadri et al. May 2016 B2
9339380 Quadri et al. May 2016 B2
9339382 Tabor et al. May 2016 B2
9358105 Marchisio et al. Jun 2016 B2
9358108 Bortlein et al. Jun 2016 B2
9387075 Bortlein et al. Jul 2016 B2
9387078 Gross et al. Jul 2016 B2
9393111 Ma et al. Jul 2016 B2
9421094 Schweich, Jr. et al. Aug 2016 B2
9433574 Martin et al. Sep 2016 B2
9480559 Vidlund et al. Nov 2016 B2
9486313 Stacchino et al. Nov 2016 B2
9504835 Graindorge Nov 2016 B2
9554906 Aklog et al. Jan 2017 B2
9610159 Christianson et al. Apr 2017 B2
9629719 Rothstein et al. Apr 2017 B2
9675454 Vidlund et al. Jun 2017 B2
9681951 Ratz et al. Jun 2017 B2
9687342 Figulla et al. Jun 2017 B2
9687343 Bortlein et al. Jun 2017 B2
9693859 Braido et al. Jul 2017 B2
9693862 Campbell et al. Jul 2017 B2
9694121 Alexander et al. Jul 2017 B2
9700409 Braido et al. Jul 2017 B2
9700411 Klima et al. Jul 2017 B2
9700413 Ruyra Baliarda et al. Jul 2017 B2
9730791 Ratz et al. Aug 2017 B2
9730792 Lutter et al. Aug 2017 B2
9730794 Carpentier et al. Aug 2017 B2
9744036 Duffy et al. Aug 2017 B2
9750605 Ganesan et al. Sep 2017 B2
9750606 Ganesan et al. Sep 2017 B2
9750607 Ganesan et al. Sep 2017 B2
9763657 Hacohen et al. Sep 2017 B2
9763658 Eigler et al. Sep 2017 B2
9763782 Solem et al. Sep 2017 B2
9770328 Macoviak et al. Sep 2017 B2
9788931 Giordano et al. Oct 2017 B2
9827092 Vidlund et al. Nov 2017 B2
9827101 Solem et al. Nov 2017 B2
9833313 Board et al. Dec 2017 B2
9833315 Vidlund et al. Dec 2017 B2
9839511 Ma et al. Dec 2017 B2
9844435 Eidenschink Dec 2017 B2
9848880 Coleman et al. Dec 2017 B2
9848981 Suri et al. Dec 2017 B2
9848983 Lashinkski et al. Dec 2017 B2
9861477 Backus et al. Jan 2018 B2
9861480 Zakai et al. Jan 2018 B2
9867695 Stacchino et al. Jan 2018 B2
9895221 Vidlund et al. Feb 2018 B2
9895223 Stacchino et al. Feb 2018 B2
9895225 Rolando et al. Feb 2018 B2
9918841 Righini et al. Mar 2018 B2
9974647 Ganesan et al. May 2018 B2
10058313 Manasse Aug 2018 B2
10065032 Ollivier Sep 2018 B2
10080659 Zentgraf et al. Sep 2018 B1
10085835 Thambar et al. Oct 2018 B2
10098733 Righini Oct 2018 B2
10117741 Schweich, Jr. et al. Nov 2018 B2
10123874 Khairkhahan et al. Nov 2018 B2
10143550 Achiluzzi Dec 2018 B2
10213301 Ganesan et al. Feb 2019 B2
10245141 Ghione et al. Apr 2019 B2
10265166 Schweich, Jr. et al. Apr 2019 B2
10285810 Schweich, Jr. et al. May 2019 B2
10449039 Ganesan et al. Oct 2019 B2
20010021872 Bailey et al. Sep 2001 A1
20010049492 Frazier et al. Dec 2001 A1
20020007219 Merrill et al. Jan 2002 A1
20020013571 Goldfarb et al. Jan 2002 A1
20020072792 Burgermeister et al. Jun 2002 A1
20020082637 Lumauig Jun 2002 A1
20020099439 Schwartz et al. Jul 2002 A1
20020138138 Yang Sep 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020173841 Ortiz et al. Nov 2002 A1
20020188350 Arru et al. Dec 2002 A1
20030078653 Vesely Apr 2003 A1
20030120340 Liska et al. Jun 2003 A1
20030139689 Shturman et al. Jul 2003 A1
20040006358 Wulfman et al. Jan 2004 A1
20040039412 Isshiki et al. Feb 2004 A1
20040044350 Martin et al. Mar 2004 A1
20040057955 O'Brien et al. Mar 2004 A1
20040082910 Constantz et al. Apr 2004 A1
20040092858 Wilson et al. May 2004 A1
20040092962 Thornton et al. May 2004 A1
20040092989 Wilson et al. May 2004 A1
20040106989 Wilson et al. Jun 2004 A1
20040117009 Cali et al. Jun 2004 A1
20040122510 Sarac Jun 2004 A1
20040127979 Wilson et al. Jul 2004 A1
20040127982 Machold et al. Jul 2004 A1
20040186558 Pavcnik et al. Sep 2004 A1
20040199191 Schwartz Oct 2004 A1
20040230117 Tosaya et al. Nov 2004 A1
20040230212 Wulfman Nov 2004 A1
20040230213 Wulfman et al. Nov 2004 A1
20040243162 Wulfman et al. Dec 2004 A1
20050007219 Ma et al. Jan 2005 A1
20050075662 Pedersen et al. Apr 2005 A1
20050075720 Nguyen et al. Apr 2005 A1
20050075727 Wheatley Apr 2005 A1
20050107661 Lau et al. May 2005 A1
20050137682 Justino Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050137700 Spence et al. Jun 2005 A1
20050137701 Salahieh et al. Jun 2005 A1
20050137702 Haug et al. Jun 2005 A1
20050228477 Grainer et al. Oct 2005 A1
20050267523 Devellian et al. Dec 2005 A1
20050273135 Chanduszko Dec 2005 A1
20060058872 Salahieh et al. Mar 2006 A1
20060106456 Machold et al. May 2006 A9
20060149360 Schwammenthal et al. Jul 2006 A1
20060167543 Bailey et al. Jul 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060253191 Salahieh et al. Nov 2006 A1
20060287719 Rowe et al. Dec 2006 A1
20070056346 Spencer et al. Mar 2007 A1
20070061010 Hauser et al. Mar 2007 A1
20070073391 Bourang et al. Mar 2007 A1
20070078302 Ortiz et al. Apr 2007 A1
20070088431 Bourang et al. Apr 2007 A1
20070142906 Figulla et al. Jun 2007 A1
20070173932 Cali et al. Jul 2007 A1
20080071369 Tuval et al. Mar 2008 A1
20080082166 Styrc et al. Apr 2008 A1
20080103586 Styrc et al. May 2008 A1
20080140189 Nguyen et al. Jun 2008 A1
20080147181 Ghione et al. Jun 2008 A1
20080161911 Lemmon et al. Jul 2008 A1
20080208332 Lamphere et al. Aug 2008 A1
20080221672 Lamphere et al. Sep 2008 A1
20080234728 Starksen et al. Sep 2008 A1
20080243245 Thambar et al. Oct 2008 A1
20080243246 Ryan et al. Oct 2008 A1
20080262603 Giaquinta et al. Oct 2008 A1
20090054969 Salahieh et al. Feb 2009 A1
20090076586 Hauser et al. Mar 2009 A1
20090076598 Salahieh et al. Mar 2009 A1
20090093670 Annest et al. Apr 2009 A1
20090105794 Ziamo et al. Apr 2009 A1
20090157174 Yoganathan et al. Jun 2009 A1
20090164006 Seguin et al. Jun 2009 A1
20090198315 Boudjemline Aug 2009 A1
20090216312 Straubinger et al. Aug 2009 A1
20090240320 Tuval et al. Sep 2009 A1
20090259292 Bonhoeffer Oct 2009 A1
20090259306 Rowe Oct 2009 A1
20090264997 Salahieh et al. Oct 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20090281609 Benichou et al. Nov 2009 A1
20090281618 Hill et al. Nov 2009 A1
20090292350 Eberhardt et al. Nov 2009 A1
20090306768 Quadri Dec 2009 A1
20090319037 Rowe et al. Dec 2009 A1
20090319038 Gurskis et al. Dec 2009 A1
20100016958 St. Goar et al. Jan 2010 A1
20100023115 Robaina et al. Jan 2010 A1
20100023117 Yoganathan et al. Jan 2010 A1
20100030330 Bobo et al. Feb 2010 A1
20100049313 Alon Feb 2010 A1
20100063586 Hasenkam et al. Mar 2010 A1
20100076376 Manasse et al. Mar 2010 A1
20100076548 Konno Mar 2010 A1
20100082094 Quadri et al. Apr 2010 A1
20100094411 Tuval et al. Apr 2010 A1
20100121436 Tuval et al. May 2010 A1
20100185275 Richter et al. Jul 2010 A1
20100217382 Chau et al. Aug 2010 A1
20100249915 Zhang Sep 2010 A1
20100249923 Alkhatib et al. Sep 2010 A1
20100298929 Thornton et al. Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20100312333 Navia et al. Dec 2010 A1
20100324554 Gifford et al. Dec 2010 A1
20110004296 Lutter et al. Jan 2011 A1
20110015722 Hauser et al. Jan 2011 A1
20110022166 Dahlgren et al. Jan 2011 A1
20110029071 Zlontnick et al. Feb 2011 A1
20110029072 Gabbay Feb 2011 A1
20110040374 Goetz et al. Feb 2011 A1
20110040375 Letac et al. Feb 2011 A1
20110066231 Cartledge et al. Mar 2011 A1
20110066233 Thornton et al. Mar 2011 A1
20110112632 Chau et al. May 2011 A1
20110137397 Chau et al. Jun 2011 A1
20110137409 Yang et al. Jun 2011 A1
20110137410 Hacohen Jun 2011 A1
20110153008 Marchand et al. Jun 2011 A1
20110172784 Richter et al. Jul 2011 A1
20110184512 Webler et al. Jul 2011 A1
20110208293 Tabor Aug 2011 A1
20110224785 Hacohen Sep 2011 A1
20110319988 Schankereli et al. Dec 2011 A1
20120022639 Hacohen et al. Jan 2012 A1
20120035703 Lutter et al. Feb 2012 A1
20120035713 Lutter et al. Feb 2012 A1
20120053680 Bolling et al. Mar 2012 A1
20120053682 Kovalsky et al. Mar 2012 A1
20120078347 Braido et al. Mar 2012 A1
20120078360 Rafiee Mar 2012 A1
20120101571 Thambar et al. Apr 2012 A1
20120165930 Gifford, III et al. Jun 2012 A1
20120179239 Quadri Jul 2012 A1
20120179244 Schankereli et al. Jul 2012 A1
20120203336 Annest Aug 2012 A1
20120283824 Lutter et al. Nov 2012 A1
20120303048 Manasse Nov 2012 A1
20130079873 Migliazza et al. Mar 2013 A1
20130123915 Giannetti et al. May 2013 A1
20130172978 Vidlund et al. Jul 2013 A1
20130190860 Sundt, III Jul 2013 A1
20130190861 Chau et al. Jul 2013 A1
20130197354 Maschke et al. Aug 2013 A1
20130197630 Azarnoush Aug 2013 A1
20130204356 Dwork et al. Aug 2013 A1
20130204358 Matheny Aug 2013 A1
20130226289 Shaolian et al. Aug 2013 A1
20130226290 Yellin et al. Aug 2013 A1
20130231735 Deem et al. Sep 2013 A1
20130238089 Lichtenstein et al. Sep 2013 A1
20130244927 Lal et al. Sep 2013 A1
20130253641 Lattouf Sep 2013 A1
20130253642 Brecker Sep 2013 A1
20130253643 Rolando et al. Sep 2013 A1
20130259337 Guhring et al. Oct 2013 A1
20130261737 Costello Oct 2013 A1
20130261738 Clague et al. Oct 2013 A1
20130261739 Kuehn Oct 2013 A1
20130261741 Accola Oct 2013 A1
20130268066 Rowe Oct 2013 A1
20130274870 Lombardi et al. Oct 2013 A1
20130282059 Ketal et al. Oct 2013 A1
20130282060 Tuval Oct 2013 A1
20130282110 Schweich, Jr. et al. Oct 2013 A1
20130289642 Hedberg et al. Oct 2013 A1
20130289717 Solem Oct 2013 A1
20130289718 Tsukashima et al. Oct 2013 A1
20130296851 Boronyak et al. Nov 2013 A1
20130296999 Burriesci et al. Nov 2013 A1
20130304180 Green et al. Nov 2013 A1
20130304181 Green et al. Nov 2013 A1
20130304197 Buchbinder et al. Nov 2013 A1
20130304198 Solem Nov 2013 A1
20130304200 McLean et al. Nov 2013 A1
20130309292 Andersen Nov 2013 A1
20130310436 Lowes et al. Nov 2013 A1
20130310925 Eliasen et al. Nov 2013 A1
20130310928 Morriss et al. Nov 2013 A1
20130317603 McLean Nov 2013 A1
20130325110 Khalil et al. Dec 2013 A1
20130325114 McLean et al. Dec 2013 A1
20130331864 Jelich et al. Dec 2013 A1
20130338684 Hausen Dec 2013 A1
20130338763 Rowe et al. Dec 2013 A1
20130338766 Hastings et al. Dec 2013 A1
20130345797 Dahlgren et al. Dec 2013 A1
20130345803 Bergheim, III Dec 2013 A1
20140005778 Buchbinder et al. Jan 2014 A1
20140018906 Rafiee Jan 2014 A1
20140018913 Cartledge et al. Jan 2014 A1
20140023261 Watanabe et al. Jan 2014 A1
20140025164 Montorfano et al. Jan 2014 A1
20140031928 Murphy et al. Jan 2014 A1
20140046219 Sauter et al. Feb 2014 A1
20140046436 Kheradvar Feb 2014 A1
20140052237 Lane et al. Feb 2014 A1
20140052240 Zhang Feb 2014 A1
20140056906 Yue et al. Feb 2014 A1
20140066895 Kipperman Mar 2014 A1
20140067048 Chau et al. Mar 2014 A1
20140067052 Chau et al. Mar 2014 A1
20140067054 Chau et al. Mar 2014 A1
20140088071 Nakai et al. Mar 2014 A1
20140088680 Costello et al. Mar 2014 A1
20140088693 Seguin et al. Mar 2014 A1
20140088695 Figulla et al. Mar 2014 A1
20140094906 Spence et al. Apr 2014 A1
20140107775 Hjelle et al. Apr 2014 A1
20140114404 Gammie et al. Apr 2014 A1
20140114407 Rajamannan Apr 2014 A1
20140121763 Duffy et al. May 2014 A1
20140128965 Rafiee May 2014 A1
20140135913 Lichtenstein et al. May 2014 A1
20140163652 Witzel et al. Jun 2014 A1
20140163668 Rafiee Jun 2014 A1
20140172076 Jonsson et al. Jun 2014 A1
20140172084 Callas et al. Jun 2014 A1
20140172085 Quadri et al. Jun 2014 A1
20140172086 Quadri et al. Jun 2014 A1
20140179993 Alexander et al. Jun 2014 A1
20140180401 Quill et al. Jun 2014 A1
20140188108 Goodine et al. Jul 2014 A1
20140188215 Hlavka et al. Jul 2014 A1
20140200662 Eftel et al. Jul 2014 A1
20140207011 Righini et al. Jul 2014 A1
20140214159 Vidlund et al. Jul 2014 A1
20140219524 Takeguchi et al. Aug 2014 A1
20140222040 Park et al. Aug 2014 A1
20140222138 Machold et al. Aug 2014 A1
20140228942 Krahbichler Aug 2014 A1
20140228946 Chau et al. Aug 2014 A1
20140242086 Lal et al. Aug 2014 A1
20140243860 Morris et al. Aug 2014 A1
20140243954 Shannon Aug 2014 A1
20140243964 Venkatasubramanian Aug 2014 A1
20140249621 Eidenschink Sep 2014 A1
20140257101 Gaudiani Sep 2014 A1
20140257466 Board et al. Sep 2014 A1
20140257467 Lane et al. Sep 2014 A1
20140257473 Rajamannan Sep 2014 A1
20140257475 Gross et al. Sep 2014 A1
20140275757 Goodwin et al. Sep 2014 A1
20140276395 Wilson et al. Sep 2014 A1
20140276609 Magee et al. Sep 2014 A1
20140276782 Paskar Sep 2014 A1
20140276971 Kovach Sep 2014 A1
20140277119 Akpinar Sep 2014 A1
20140277390 Ratz et al. Sep 2014 A1
20140277404 Wilson et al. Sep 2014 A1
20140277405 Wilson et al. Sep 2014 A1
20140277406 Arcidi Sep 2014 A1
20140277407 Dale et al. Sep 2014 A1
20140277408 Folan Sep 2014 A1
20140277409 Bortlein et al. Sep 2014 A1
20140277410 Bortlein et al. Sep 2014 A1
20140277411 Bortlein et al. Sep 2014 A1
20140277412 Bortlein et al. Sep 2014 A1
20140277420 Migliazza et al. Sep 2014 A1
20140277422 Ratz et al. Sep 2014 A1
20140288480 Zimmerman et al. Sep 2014 A1
20140296878 Oz et al. Oct 2014 A1
20140296969 Tegels et al. Oct 2014 A1
20140296970 Ekvall et al. Oct 2014 A1
20140296971 Tegels et al. Oct 2014 A1
20140296975 Tegels et al. Oct 2014 A1
20140303719 Cox et al. Oct 2014 A1
20140303721 Fung et al. Oct 2014 A1
20140309727 Lamelas et al. Oct 2014 A1
20140309730 Alon et al. Oct 2014 A1
20140309731 Quadri et al. Oct 2014 A1
20140309732 Solem Oct 2014 A1
20140316516 Vidlund et al. Oct 2014 A1
20140324164 Gross et al. Oct 2014 A1
20140358222 Gorman, III et al. Dec 2014 A1
20140358224 Tegels et al. Dec 2014 A1
20140364944 Lutter et al. Dec 2014 A1
20140371843 Wilson et al. Dec 2014 A1
20140371844 Dale et al. Dec 2014 A1
20140371846 Wilson et al. Dec 2014 A1
20140379074 Spence et al. Dec 2014 A1
20140379076 Vidlund et al. Dec 2014 A1
20150005874 Vidlund et al. Jan 2015 A1
20150005875 Tuval et al. Jan 2015 A1
20150025623 Granada et al. Jan 2015 A1
20150032127 Gammie et al. Jan 2015 A1
20150045878 Rowe Feb 2015 A1
20150066140 Quadri et al. Mar 2015 A1
20150094802 Buchbinder et al. Apr 2015 A1
20150094803 Navia Apr 2015 A1
20150100116 Mohl et al. Apr 2015 A1
20150112427 Schweich, Jr. et al. Apr 2015 A1
20150112429 Khairkhahan et al. Apr 2015 A1
20150112433 Schweich, Jr. et al. Apr 2015 A1
20150119978 Tegels et al. Apr 2015 A1
20150119981 Khairkhahan et al. Apr 2015 A1
20150119982 Quill et al. Apr 2015 A1
20150127091 Cecere et al. May 2015 A1
20150127096 Rowe et al. May 2015 A1
20150142101 Coleman et al. May 2015 A1
20150142103 Vidlund May 2015 A1
20150142105 Bolling et al. May 2015 A1
20150150678 Brecker Jun 2015 A1
20150157458 Thambar et al. Jun 2015 A1
20150157459 Macoviak et al. Jun 2015 A1
20150164637 Khairkhahan et al. Jun 2015 A1
20150164641 Annest Jun 2015 A1
20150173897 Raanani et al. Jun 2015 A1
20150173898 Drasler et al. Jun 2015 A1
20150173900 Hauser et al. Jun 2015 A1
20150190229 Seguin Jul 2015 A1
20150196390 Ma et al. Jul 2015 A1
20150196393 Vidlund et al. Jul 2015 A1
20150202043 Zakai et al. Jul 2015 A1
20150209137 Quadri et al. Jul 2015 A1
20150209139 Granada et al. Jul 2015 A1
20150216655 Lane et al. Aug 2015 A1
20150216661 Hacohen et al. Aug 2015 A1
20150223802 Tegzes Aug 2015 A1
20150223934 Vidlund et al. Aug 2015 A1
20150223935 Subramanian et al. Aug 2015 A1
20150230920 Alfieri et al. Aug 2015 A1
20150230921 Chau et al. Aug 2015 A1
20150238312 Lashinski Aug 2015 A1
20150238313 Spence et al. Aug 2015 A1
20150250590 Gries et al. Sep 2015 A1
20150257877 Hernandez Sep 2015 A1
20150257878 Lane et al. Sep 2015 A1
20150257879 Bortlein et al. Sep 2015 A1
20150257881 Bortlein et al. Sep 2015 A1
20150257882 Bortlein et al. Sep 2015 A1
20150272737 Dale et al. Oct 2015 A1
20150305861 Annest Oct 2015 A1
20150305864 Quadri et al. Oct 2015 A1
20150313739 Hummen et al. Nov 2015 A1
20150320553 Chau et al. Nov 2015 A1
20150327999 Board et al. Nov 2015 A1
20150328000 Ratz et al. Nov 2015 A1
20150342733 Alkhatib et al. Dec 2015 A1
20150351906 Hammer et al. Dec 2015 A1
20150351908 Keranen et al. Dec 2015 A1
20150359628 Keranen Dec 2015 A1
20150359629 Ganesan et al. Dec 2015 A1
20150359631 Sheahan et al. Dec 2015 A1
20150366666 Khairkhahan et al. Dec 2015 A1
20150374495 Ruyra Baliarda et al. Dec 2015 A1
20160000983 Mohl et al. Jan 2016 A1
20160015513 Lashinski et al. Jan 2016 A1
20160015514 Lashinski et al. Jan 2016 A1
20160015515 Lashinski et al. Jan 2016 A1
20160015543 Perouse et al. Jan 2016 A1
20160030171 Quijano et al. Feb 2016 A1
20160038246 Wang et al. Feb 2016 A1
20160038280 Morriss et al. Feb 2016 A1
20160038283 Divekar et al. Feb 2016 A1
20160038286 Yellin et al. Feb 2016 A1
20160074160 Christianson et al. Mar 2016 A1
20160106539 Buchbinder et al. Apr 2016 A1
20160113764 Sheahan et al. Apr 2016 A1
20160113765 Ganesan et al. Apr 2016 A1
20160113766 Ganesan et al. Apr 2016 A1
20160113768 Ganesan et al. Apr 2016 A1
20160120643 Kupumbati May 2016 A1
20160143730 Kheradvar May 2016 A1
20160151154 Gorman, III et al. Jun 2016 A1
20160151156 Seguin et al. Jun 2016 A1
20160151552 Solem Jun 2016 A1
20160157999 Lane et al. Jun 2016 A1
20160158000 Granada et al. Jun 2016 A1
20160158001 Wallace et al. Jun 2016 A1
20160158002 Wallace et al. Jun 2016 A1
20160158003 Wallace et al. Jun 2016 A1
20160158415 Strasly et al. Jun 2016 A1
20160184095 Spence et al. Jun 2016 A1
20160206280 Vidlund et al. Jul 2016 A1
20160206424 Al-Jilaihawi et al. Jul 2016 A1
20160262881 Schankereli et al. Sep 2016 A1
20160317290 Chau et al. Nov 2016 A1
20170079790 Vidlund et al. Mar 2017 A1
20170100248 Tegels et al. Apr 2017 A1
20170100250 Marsot et al. Apr 2017 A1
20170119526 Luong et al. May 2017 A1
20170128198 Cartledge et al. May 2017 A1
20170128205 Tamir et al. May 2017 A1
20170128206 Rafiee et al. May 2017 A1
20170128208 Christianson et al. May 2017 A1
20170156860 Lashinski Jun 2017 A1
20170165054 Benson et al. Jun 2017 A1
20170165055 Hauser et al. Jun 2017 A1
20170165064 Nyuli et al. Jun 2017 A1
20170172737 Kuetting et al. Jun 2017 A1
20170181851 Annest Jun 2017 A1
20170189177 Schweich, Jr. et al. Jul 2017 A1
20170189179 Ratz et al. Jul 2017 A1
20170189180 Alkhatib et al. Jul 2017 A1
20170189181 Alkhatib et al. Jul 2017 A1
20170196688 Christianson et al. Jul 2017 A1
20170231762 Quadri et al. Aug 2017 A1
20170231763 Yellin et al. Aug 2017 A1
20170258585 Marguez et al. Sep 2017 A1
20170266001 Vidlund et al. Sep 2017 A1
20170281345 Yang et al. Oct 2017 A1
20170290659 Ulmer et al. Oct 2017 A1
20170296339 Thambar et al. Oct 2017 A1
20170319333 Tegels et al. Nov 2017 A1
20170325941 Wallace et al. Nov 2017 A1
20170325945 Dale et al. Nov 2017 A1
20170325948 Wallace et al. Nov 2017 A1
20170333186 Spargias Nov 2017 A1
20170333188 Carpentier et al. Nov 2017 A1
20170340440 Ratz et al. Nov 2017 A1
20170348098 Rowe et al. Dec 2017 A1
20170348100 Lane et al. Dec 2017 A1
20170354496 Quadri et al. Dec 2017 A1
20170354497 Quadri et al. Dec 2017 A1
20170354499 Granada et al. Dec 2017 A1
20170360426 Hacohen et al. Dec 2017 A1
20170360549 Lashinski et al. Dec 2017 A1
20170360558 Ma Dec 2017 A1
20170360585 White Dec 2017 A1
20180161585 Ollivier Jun 2018 A1
20180214263 Rolando et al. Aug 2018 A1
20180221147 Ganesan et al. Aug 2018 A1
20180235753 Ganesan et al. Aug 2018 A1
20180338832 Ganesan et al. Nov 2018 A1
20190000618 Schweich, Jr. et al. Jan 2019 A1
20190029814 Schweich, Jr. et al. Jan 2019 A1
20190142581 Maiso et al. May 2019 A1
20190183641 Ganesan et al. Jun 2019 A1
20190192292 Schweich, Jr. et al. Jun 2019 A1
Foreign Referenced Citations (362)
Number Date Country
1440261 Sep 2003 CN
101076290 Nov 2007 CN
101291637 Oct 2008 CN
103491900 Jan 2014 CN
19605042 Jan 1998 DE
102006052564 Dec 2007 DE
186104 Jul 1986 EP
0224080 Jul 1992 EP
1512383 Mar 2005 EP
1088529 Jun 2005 EP
1545371 Jun 2005 EP
1551274 Jul 2005 EP
1629794 Mar 2006 EP
1646332 Apr 2006 EP
1702247 Sep 2006 EP
1734903 Dec 2006 EP
1891914 Feb 2008 EP
1967164 Sep 2008 EP
2026280 Feb 2009 EP
2033581 Mar 2009 EP
2037829 Mar 2009 EP
2081519 Jul 2009 EP
2111190 Oct 2009 EP
2142143 Jan 2010 EP
2167742 Mar 2010 EP
2014257 Sep 2010 EP
2278944 Feb 2011 EP
2033597 Mar 2011 EP
2399527 Mar 2011 EP
2306821 Apr 2011 EP
2327429 Jun 2011 EP
2165651 Aug 2011 EP
1719476 Nov 2011 EP
2399527 Dec 2011 EP
2400924 Jan 2012 EP
2400926 Jan 2012 EP
2410947 Feb 2012 EP
2416739 Feb 2012 EP
2419050 Feb 2012 EP
2444031 Apr 2012 EP
2488126 Aug 2012 EP
2509538 Oct 2012 EP
2549955 Jan 2013 EP
2549956 Jan 2013 EP
2566416 Mar 2013 EP
2586492 May 2013 EP
2618784 Jul 2013 EP
2623068 Aug 2013 EP
2626013 Aug 2013 EP
2629699 Aug 2013 EP
2633457 Sep 2013 EP
2637659 Sep 2013 EP
2641569 Sep 2013 EP
2644158 Oct 2013 EP
2654624 Oct 2013 EP
2656794 Oct 2013 EP
2656795 Oct 2013 EP
2656796 Oct 2013 EP
2667823 Dec 2013 EP
2670358 Dec 2013 EP
2676640 Dec 2013 EP
2688041 Jan 2014 EP
2695586 Feb 2014 EP
2697721 Feb 2014 EP
2713953 Apr 2014 EP
2714068 Apr 2014 EP
2723272 Apr 2014 EP
2723273 Apr 2014 EP
2723277 Apr 2014 EP
2739214 Jun 2014 EP
2741711 Jun 2014 EP
2750630 Jul 2014 EP
2750631 Jul 2014 EP
2755562 Jul 2014 EP
2755602 Jul 2014 EP
2757962 Jul 2014 EP
2777616 Sep 2014 EP
2777617 Sep 2014 EP
2782523 Oct 2014 EP
2785282 Oct 2014 EP
2786817 Oct 2014 EP
2790609 Oct 2014 EP
2793751 Oct 2014 EP
2229921 Nov 2014 EP
2809263 Dec 2014 EP
2810620 Dec 2014 EP
2814428 Dec 2014 EP
2814429 Dec 2014 EP
2819617 Jan 2015 EP
2819618 Jan 2015 EP
2819619 Jan 2015 EP
2833836 Feb 2015 EP
2838475 Feb 2015 EP
2839815 Feb 2015 EP
2844190 Mar 2015 EP
2849680 Mar 2015 EP
2849681 Mar 2015 EP
2852354 Apr 2015 EP
2861186 Apr 2015 EP
2870933 May 2015 EP
2873011 May 2015 EP
2875797 May 2015 EP
2760375 Jun 2015 EP
2882374 Jun 2015 EP
2886082 Jun 2015 EP
2886083 Jun 2015 EP
2886084 Jun 2015 EP
2895111 Jul 2015 EP
2250976 Aug 2015 EP
2901966 Aug 2015 EP
2907479 Aug 2015 EP
2945572 Nov 2015 EP
2948094 Dec 2015 EP
2948102 Dec 2015 EP
2964152 Jan 2016 EP
2967859 Jan 2016 EP
2967860 Jan 2016 EP
2967866 Jan 2016 EP
2968847 Jan 2016 EP
2981208 Feb 2016 EP
2982336 Feb 2016 EP
2999433 Mar 2016 EP
3003187 Apr 2016 EP
3003219 Apr 2016 EP
3003220 Apr 2016 EP
3010447 Apr 2016 EP
3013281 May 2016 EP
3017792 May 2016 EP
3021792 May 2016 EP
3023117 May 2016 EP
3027143 Jun 2016 EP
3033048 Jun 2016 EP
3037064 Jun 2016 EP
3050541 Aug 2016 EP
3079633 Oct 2016 EP
3102152 Dec 2016 EP
2470119 May 2017 EP
2999436 May 2017 EP
3184081 Jun 2017 EP
3191027 Jul 2017 EP
2611389 Aug 2017 EP
3082656 Aug 2017 EP
3206628 Aug 2017 EP
2010103 Sep 2017 EP
3223751 Oct 2017 EP
3027144 Nov 2017 EP
3110368 Nov 2017 EP
3110369 Nov 2017 EP
3132773 Nov 2017 EP
6504516 May 1994 JP
H10258124 Sep 1998 JP
2002509756 Apr 2002 JP
2005280917 Oct 2005 JP
2008528117 Jul 2008 JP
2008541863 Nov 2008 JP
2009195712 Sep 2009 JP
2010518947 Jun 2010 JP
5219518 Jun 2013 JP
WO-1992017118 Oct 1992 WO
WO-1995016407 Jun 1995 WO
WO-1999004730 Feb 1999 WO
WO-1999039648 Aug 1999 WO
WO-1999049799 Oct 1999 WO
WO-2001010343 Feb 2001 WO
WO-2002003892 Jan 2002 WO
WO-2002028421 Apr 2002 WO
WO-2002039908 May 2002 WO
WO-2003043685 May 2003 WO
WO-2004084746 Oct 2004 WO
WO-2004093728 Nov 2004 WO
WO-2004096097 Nov 2004 WO
WO-2004112657 Dec 2004 WO
WO-2005002466 Jan 2005 WO
WO-2005007219 Jan 2005 WO
WO-2005009285 Feb 2005 WO
WO-2005009506 Feb 2005 WO
WO-2005087140 Sep 2005 WO
WO-2006041877 Apr 2006 WO
WO-2006063199 Jun 2006 WO
WO-2007008371 Jan 2007 WO
WO-2007067820 Jun 2007 WO
WO-2007098232 Aug 2007 WO
WO-2008022077 Feb 2008 WO
WO-2008028569 Mar 2008 WO
WO-2008035337 Mar 2008 WO
WO-2008103497 Aug 2008 WO
WO-2008103722 Aug 2008 WO
WO-20081 29405 Oct 2008 WO
WO-2009045338 Apr 2009 WO
WO-2009091509 Jul 2009 WO
WO-2010006627 Jan 2010 WO
WO-2010008549 Jan 2010 WO
WO-2010057262 May 2010 WO
WO-2010080594 Jul 2010 WO
WO-2010098857 Sep 2010 WO
WO-2010099032 Sep 2010 WO
WO-2010117680 Oct 2010 WO
WO-2010121076 Oct 2010 WO
WO-2011025981 Mar 2011 WO
WO-2011047168 Apr 2011 WO
WO-2011051043 May 2011 WO
WO-2011057087 May 2011 WO
WO-2011072084 Jun 2011 WO
WO-2011106137 Sep 2011 WO
WO-2011106544 Sep 2011 WO
WO-2011111047 Sep 2011 WO
WO-2011137531 Nov 2011 WO
WO-2011139747 Nov 2011 WO
WO-2012011018 Jan 2012 WO
WO-2012011108 Jan 2012 WO
WO-2012027487 Mar 2012 WO
WO-2012035279 Mar 2012 WO
WO-2012040655 Mar 2012 WO
WO-2012047644 Apr 2012 WO
WO-2012052718 Apr 2012 WO
WO-2012055498 May 2012 WO
WO-2012087842 Jun 2012 WO
WO-2012095455 Jul 2012 WO
WO-2012102928 Aug 2012 WO
WO-2012106602 Aug 2012 WO
WO-2012118508 Sep 2012 WO
WO-2012118816 Sep 2012 WO
WO-2012118894 Sep 2012 WO
WO-2012177942 Dec 2012 WO
WO-2013021374 Feb 2013 WO
WO-2013021375 Feb 2013 WO
WO-2013028387 Feb 2013 WO
WO-2013059743 Apr 2013 WO
WO-2013059747 Apr 2013 WO
WO-2013114214 Aug 2013 WO
WO-2013120181 Aug 2013 WO
WO-2013123059 Aug 2013 WO
WO-2013128432 Sep 2013 WO
WO-2013130641 Sep 2013 WO
WO-2013131925 Sep 2013 WO
WO-2013140318 Sep 2013 WO
WO-2013148017 Oct 2013 WO
WO-2013148018 Oct 2013 WO
WO-2013148019 Oct 2013 WO
WO-2013150512 Oct 2013 WO
WO-2013152161 Oct 2013 WO
WO-2013158613 Oct 2013 WO
WO-2013169448 Nov 2013 WO
WO-2013175468 Nov 2013 WO
WO-2013176583 Nov 2013 WO
WO-2013188077 Dec 2013 WO
WO-2013192107 Dec 2013 WO
WO-2014036113 Mar 2014 WO
WO-2014043527 Mar 2014 WO
WO-2014047111 Mar 2014 WO
WO-2014047325 Mar 2014 WO
WO-2014055981 Apr 2014 WO
WO-2014059432 Apr 2014 WO
WO-2014064694 May 2014 WO
WO-2014066365 May 2014 WO
WO-2014089424 Jun 2014 WO
WO-2014093861 Jun 2014 WO
WO-2014111918 Jul 2014 WO
WO-2014114794 Jul 2014 WO
WO-2014114795 Jul 2014 WO
WO-2014114796 Jul 2014 WO
WO-2014114798 Jul 2014 WO
WO-2014116502 Jul 2014 WO
WO-2014121280 Aug 2014 WO
WO-2014128705 Aug 2014 WO
WO-2014134277 Sep 2014 WO
WO-2014138194 Sep 2014 WO
WO-2014138284 Sep 2014 WO
WO-2014138482 Sep 2014 WO
WO-2014138868 Sep 2014 WO
WO-2014144100 Sep 2014 WO
WO-2014144937 Sep 2014 WO
WO-2014145338 Sep 2014 WO
WO-2014147336 Sep 2014 WO
WO-2014152306 Sep 2014 WO
WO-2014152375 Sep 2014 WO
WO-2014152503 Sep 2014 WO
WO-2014153544 Sep 2014 WO
WO-2014158617 Oct 2014 WO
WO-2014162181 Oct 2014 WO
WO-2014162306 Oct 2014 WO
WO-2014163705 Oct 2014 WO
WO-2014168655 Oct 2014 WO
WO-2014179391 Nov 2014 WO
WO-2014181336 Nov 2014 WO
WO-2014189974 Nov 2014 WO
WO-2014191994 Dec 2014 WO
WO-2014194178 Dec 2014 WO
WO-2014201384 Dec 2014 WO
WO-2014201452 Dec 2014 WO
WO-2014205064 Dec 2014 WO
WO-2014207699 Dec 2014 WO
WO-2014210124 Dec 2014 WO
WO-2014210299 Dec 2014 WO
WO-2015009503 Jan 2015 WO
WO-2015020971 Feb 2015 WO
WO-2015028986 Mar 2015 WO
WO-2015051430 Apr 2015 WO
WO-2015052663 Apr 2015 WO
WO-2015057407 Apr 2015 WO
WO-2015057735 Apr 2015 WO
WO-2015057995 Apr 2015 WO
WO-2015061378 Apr 2015 WO
WO-2015061431 Apr 2015 WO
WO-2015061463 Apr 2015 WO
WO-2015061533 Apr 2015 WO
WO-2015075128 May 2015 WO
WO-2015081775 Jun 2015 WO
WO-2015089334 Jun 2015 WO
WO-2015092554 Jun 2015 WO
WO-2015118464 Aug 2015 WO
WO-2015120122 Aug 2015 WO
WO-2015125024 Aug 2015 WO
WO-2015127264 Aug 2015 WO
WO-2015127283 Aug 2015 WO
WO-2015128739 Sep 2015 WO
WO-2015128741 Sep 2015 WO
WO-2015128747 Sep 2015 WO
WO-2015132667 Sep 2015 WO
WO-2015132668 Sep 2015 WO
WO-2015135050 Sep 2015 WO
WO-2015142648 Sep 2015 WO
WO-2015142834 Sep 2015 WO
WO-2015148241 Oct 2015 WO
WO-2015171190 Nov 2015 WO
WO-2015171743 Nov 2015 WO
WO-2015179181 Nov 2015 WO
WO-2015191604 Dec 2015 WO
WO-2015191839 Dec 2015 WO
WO-2015195823 Dec 2015 WO
WO-2016011185 Jan 2016 WO
WO-2016020918 Feb 2016 WO
WO-2016027272 Feb 2016 WO
WO-2016059533 Apr 2016 WO
WO-2016065158 Apr 2016 WO
WO-2016073741 May 2016 WO
WO-2016083551 Jun 2016 WO
WO-2016093877 Jun 2016 WO
WO-2016097337 Jun 2016 WO
WO-2016108181 Jul 2016 WO
WO-2016133950 Aug 2016 WO
WO-2016150806 Sep 2016 WO
WO-2016201024 Dec 2016 WO
WO-2016209970 Dec 2016 WO
WO-2017011697 Jan 2017 WO
WO-2017062640 Apr 2017 WO
WO-2017096157 Jun 2017 WO
WO-2017100927 Jun 2017 WO
WO-2017101232 Jun 2017 WO
WO-2017117388 Jul 2017 WO
WO-2017127939 Aug 2017 WO
WO-2017173331 Oct 2017 WO
WO-2017196511 Nov 2017 WO
WO-2017196909 Nov 2017 WO
WO-2017196977 Nov 2017 WO
WO-2017197064 Nov 2017 WO
WO-2017218671 Dec 2017 WO
WO-2018017886 Jan 2018 WO
WO-2018029680 Feb 2018 WO
WO-2018167536 Sep 2018 WO
WO-2019069145 Apr 2019 WO
WO-2019209927 Oct 2019 WO
Non-Patent Literature Citations (52)
Entry
US 9,265,606 B2, 02/2016, Buchbinder et al. (withdrawn)
Bernard et al., “Aortic Valve Area Evolution After Percutaneous Aortic Valvuloplasty,” European Heart Journal, Jul. 1990, vol. 11 (2), pp. 98-107.
BlueCross BlueShield of Northern Carolina Corporate Medical Policy “Balloon valvuloplasty, Percutaneous”, (Jun. 1994).
Cimino et al., “Physics of Ultrasonic Surgery Using Tissue Fragmentation: Part I and Part II”, Ultrasound in Medicine and Biologyl, Jun. 1996, vol. 22 (1), pp. 89-100, and pp. 101-117.
Cimino, “Ultrasonic Surgery: Power Quantification and Efficiency Optimization”, Aesthetic Surgery Journal, Feb. 2001, pp. 233-241.
Cowell et al., “A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis,” NEJM, Jun. 2005, vol. 352 (23), pp. 2389-2397.
De Korte et al., “Characterization of Plaque Components and Vulnerability with Intravascular Ultrasound Elastography”, Phys. Med. Biol., Feb. 2000, vol. 45, pp. 1465-1475.
European Search Report dated Mar. 13, 2015 for European Application. No. 05853460.3.
Feldman, “Restenosis Following Successful Balloon Valvuloplasty: Bone Formation in Aortic Valve Leaflets”, Cathet Cardiovasc Diagn, May 1993, vol. 29 (1), pp. 1-7.
Fitzgerald et al., “Intravascular Sonotherapy Decreased Neointimal Hyperplasia After Stent Implantation in Swine”, Circulation, Feb. 2001, vol. 103, pp. 1828-1831.
Freeman et al., “Ultrasonic Aortic Valve Decalcification: Serial Doppler Echocardiographic Follow Up”, J Am Coll Cardiol., Sep. 1990, vol. 16 (3), pp. 623-630.
Greenleaf et al., “Selected Methods for Imaging Elastic Properties of Biological Tissues”, Annu. Rev. Biomed. Eng., Apr. 2003, vol. 5, pp. 57-78.
Gunn et al., “New Developments in Therapeutic Ultrasound-Assisted Coronary Angioplasty”, Curr Interv Cardiol Rep., Dec. 1990, vol. 1 (4), pp. 281-290.
Guzman et al., “Bioeffects Caused by Changes in Acoustic Cavitation Bubble Density and Cell Concentration: A Unified Explanation Based on Cell-to-Bubble Ratio and Blast Radius”, Ultrasound in Med. & Biol., Mar. 2003, vol. 29 (8), pp. 1211-1222.
Hallgrimsson et al., “Chronic Non-Rheumatic Aortic Valvular Disease: a Population Study Based on Autopsies”, J Chronic Dis., Jun. 1979, vol. 32 (5), pp. 355-363.
International Search Report and Written Opinion dated Sep. 11, 2018 for PCT Application No. PCT/US2018/038841, 15 pages.
International Search Report and Written Opinion dated Sep. 4, 2018 for PCT Application No. PCT/US2018/027966, 17 pages.
International Search Report and Written Opinion dated Jul. 11, 2018 for PCT Application No. PCT/US2018/027990, 15 pages.
International Search Report and Written Opinion dated Jun. 28, 2018 for PCT Application No. PCT/US2018/027983, 15 pages.
International Search Report and Written Opinion dated Aug. 3, 2018 for PCT Application No. PCT/US2018/035086, 15 pages.
International Search Report and Written Opinion dated Aug. 9, 2018 for PCT Application No. PCT/US2018/035081, 11 pages.
International Search Report and Written Opinion dated Sep. 11, 2018 for PCT Application No. PCT/US2018/038847, 18 pages.
Isner et al., “Contrasting Histoarchitecture of Calcified Leaflets from Stenotic Bicuspid Versus Stenotic Tricuspid Aortic Valves”, J Am Coll Cardiol., Apr. 1990, vol. 15 (5), p. 1104-1108.
Lung et al., “A Prospective Survey of Patients with Valvular Heart Disease in Europe: The Euro Heart Survey on Valvular Heart Disease”, Euro Heart Journal, Mar. 2003, vol. 24, pp. 1231-1243.
McBride et al. “Aortic Valve Decalcification”, J Thorac Cardiovas-Surg, Jul. 1990, vol. 100, pp. 36-42.
Miller et al., “Lysis and Sonoporation of Epidermoid and Phagocytic Monolayer Cells by Diagnostic Ultrasound Activation of Contrast Agent Gas Bodies”, Ultrasound in Med. & Biol., May 2007, vol. 27 (8), pp. 1107-1113.
Mohler, “Mechanisms of Aortic Valve Calcificaion”, Am J Cardiol, Dec. 2004, vol. 94 (11), pp. 1396-1402.
Otto et al., “Three-Year Outcome After Balloon Aortic Valvuloplasty. Insights into Prognosis of Valvular Aortic Stenosis”, Circulation, Feb. 1994, vol. 89, pp. 642-650.
Passik et al., “Temporal Changes in the Causes of Aortic Stenosis: A Surgical Pathologic Study of 646 Cases”, Mayo Clin Proc, Feb. 1987, vol. 62, pp. 19-123.
Quaden et al., “Percutaneous Aortic Valve Replacement: Resection Before Implantation”, Eur J Cardiothorac Surg, Jan. 2005, vol. 27, pp. 836-840.
Riebman et al., “New Concepts in the Management of Patients with Aortic Valve Disease”, Abstract, Valvular Heart Disease, JACC, Mar. 2004, p. 34A.
Rosenschein et al., “Percutaneous Transluminal Therapy of Occluded Saphenous Vein Grafts” Circulation, Jan. 1999, vol. 99, pp. 26-29.
Sakata et al., “Percutaneous Balloon Aortic Valvuloplasty: Antegrade Transseptal vs. Conventional Retrograde Transarterial Approach”, Catheter Cardiovasc Interv., Mar. 2005, vol. 64 (3), pp. 314-321.
Sasaki et al., “Scanning Electron Microscopy and Fourier Transformed Infrared Spectroscopy Analysis of Bone Removal Using Er:YAG and CO2 Lasers”, J Periodontol., Jun. 2002, vol. 73 (6), pp. 643-652.
Search Report and Written Opinion dated Dec. 10, 2012 for PCT Application No. PCT/US2012/043636.
Search Report and Written Opinion dated Dec. 6, 2016 for PCT Application No. PCT/US2016/047831.
Search Report and Written Opinion dated Apr. 19, 2014 PCT Application No. PCT/US2012/061215.
Search Report and Written Opinion dated Apr. 19, 2014 PCT Application No. PCT/US2012/061219.
Search Report and Written Opinion dated Mar. 2, 2015 for PCT Application No. PCT/US2014/029549.
Search Report and Written Opinion dated May 1, 2012 for PCT Application No. PCT/US2011/065627.
Search Report and Written Opinion dated May 22, 2007 for PCT Application No. PCT/US2005/044543.
Search Report and Written Opinion dated Oct. 20, 2014 for PCT Application No. PCT/US2014/038849.
Search Report and Written Opinion dated Sep. 4, 2014 for PCT Application No. PCT/US2014/014704.
The CoreValve System Medtronic, 2012, 4 Pages.
Van Den Brand et al., “Histological Changes in the Aortic Valve after Balloon Dilation: Evidence for a Delayed Healing Process”, Br Heart J, Jun. 1992,vol. 67, pp. 445-459.
Verdaadadonk et al., “The Mechanism of Action of the Ultrasonic Tissue Resectors Disclosed Using High-Speed and Thermal Imaging Techniques”, SPIE, Jan. 1999, vol. 3594, pp. 221-231.
Voelker et al., “Inoperative Valvuloplasty in Calcific Aortic Stenosis: a Study Comparing the Mechanism of a Novel Expandable Device with Conventional Balloon Dilation”, Am Heart J., Nov. 1991, vol. 122 (5), pp. 1327-1333.
Waller et al., “Catheter Balloon Valvuloplasty of Stenotic Aortic Valves. Part II: Balloon Valvuloplasty During Life Subsequent Tissue Examination”, Clin Cardiol., Nov. 1991, vol. 14 (11), pp. 924-930.
Wang, “Balloon Aortic Valvuloplasty”, Prog Cardiovasc Dis., Jul.-Aug. 1997, vol. 40 (1), pp. 27-36.
Wilson et al., “Elastography—The movement Begins”, Phys. Med. Biol., Jun. 2000, vol. 45, pp. 1409-1421.
Yock et al., “Catheter-Based Ultrasound Thrombolysis”, Circulation, Mar. 1997, vol. 95 (6), pp. 1411-1416.
Office action, China National Intellectual Property Administration, Appl. No. 2188002618.5, dated May 21, 2021.
Related Publications (1)
Number Date Country
20200330222 A1 Oct 2020 US
Divisions (1)
Number Date Country
Parent 15490047 Apr 2017 US
Child 16904250 US